Introduction
Adult advanced life support (ALS) includes advanced interventions after basic life support has started and when appropriate an automated external defibrillator (AED) has been used. Adult basic life support (BLS) and use of AEDs is addressed in Section 2. The transition between basic and advanced life support should be seamless as BLS will continue during and overlap with ALS interventions. This section on ALS includes the prevention of cardiac arrest, specific aspects of prehospital ALS, starting in-hospital resuscitation, the ALS algorithm, manual defibrillation, airway management during CPR, drugs and their delivery during CPR, and the treatment of peri-arrest arrhythmias. There are two changes in the presentation of these guidelines since European Resuscitation Council (ERC) Guidelines 2010. 1 There is no longer a separate section on electrical therapies 2 and the ALS aspects are now part of this section. Post-resuscitation care guidelines are presented in a new section (Section 5) that recognises the importance of the final link in the Chain of Survival. 3 These Guidelines are based on the International Liaison Committee on Resuscitation (ILCOR) 2015 Consensus on Science and Treatment Recommendations (CoSTR) for ALS. 4 The 2015 ILCOR review focused on 42 topics organised in the approximate sequence of ALS interventions: defibrillation, airway, oxygenation and ventilation, circulatory support, monitoring during CPR, and drugs during CPR. For these Guidelines the ILCOR recommendations were supplemented by focused literature reviews undertaken by the ERC ALS Writing Group for those topics not reviewed in the 2015 ILCOR CoSTR. Guidelines were drafted and agreed by the ALS Writing Group members before final approval by the ERC General Assembly and ERC Board.
Summary of changes since 2010 Guidelines
The 2015 ERC ALS Guidelines have a change in emphasis aimed at improved care and implementation of these guidelines in order to improve patient focused outcomes. 5 The 2015 ERC ALS Guidelines do not include any major changes in core ALS interventions since the previous ERC guidelines published in 2010. 1, 2 The key changes since 2010 are:
• Continuing emphasis on the use of rapid response systems for care of the deteriorating patient and prevention of in-hospital cardiac arrest.
• Continued emphasis on minimally interrupted high-quality chest compressions throughout any ALS intervention: chest compressions are paused briefly only to enable specific interventions. This includes minimising interruptions in chest compressions to attempt defibrillation.
• Keeping the focus on the use of self-adhesive pads for defibrillation and a defibrillation strategy to minimise the preshock pause, although we recognise that defibrillator paddles are used in some settings.
• There is a new section on monitoring during ALS with an increased emphasis on the use of waveform capnography to confirm and continually monitor tracheal tube placement, quality of CPR and to provide an early indication of return of spontaneous circulation (ROSC).
• There are a variety of approaches to airway management during CPR and a stepwise approach based on patient factors and the skills of the rescuer is recommended.
• The recommendations for drug therapy during CPR have not changed, but there is greater equipoise concerning the role of drugs in improving outcomes from cardiac arrest.
• The routine use of mechanical chest compression devices is not recommended, but they are a reasonable alternative in situations where sustained high-quality manual chest compressions are impractical or compromise provider safety.
• Peri-arrest ultrasound may have a role in identifying reversible causes of cardiac arrest.
• Extracorporeal life support techniques may have a role as a rescue therapy in selected patients where standard ALS measures are not successful.
3a -Prevention of in-hospital cardiac arrest
Early recognition of the deteriorating patient and prevention of cardiac arrest is the first link in the chain of survival. 3 Once cardiac arrest occurs, only about 20% of patients who have an in-hospital cardiac arrest will survive to go home. 6, 7 The key recommendations for the prevention of in-hospital cardiac arrest are unchanged since the previous guidance in 2010. 1 We suggest an approach to prevention of in-hospital cardiac arrest that includes staff education, monitoring of patients, recognition of patient deterioration, a system to call for help and an effective response -the chain of prevention. 8 
The problem
Cardiac arrest in patients in unmonitored ward areas is not usually a sudden unpredictable event. 9 Patients often have slow and progressive physiological deterioration, involving hypoxaemia and hypotension that is unnoticed or poorly managed by ward staff. [10] [11] [12] The initial cardiac arrest rhythm is usually non-shockable 6, 7 and survival to hospital discharge is poor, particularly in patients with preceding signs of respiratory depression or shock. 7, 13 Early and effective treatment might prevent some cardiac arrests, deaths and unanticipated ICU admissions. Studies conducted in hospitals with traditional cardiac arrest teams have shown that patients attended by the team but who were found not to have a cardiac arrest, have a high morbidity and mortality. [14] [15] [16] Registry data from the US suggests that hospitals with lowest incidence of IHCA also have the highest CA survival. 17 Nature of the deficiencies in the recognition and response to patient deterioration These include infrequent, late or incomplete vital signs assessments; lack of knowledge of normal vital signs values; poor design of vital signs charts; poor sensitivity and specificity of 'track and trigger' systems; failure of staff to increase monitoring or escalate care, and staff workload. [18] [19] [20] [21] [22] [23] [24] [25] [26] Problems with assessing and treating airway, breathing and circulation abnormalities as well organisational problems such as poor communication, lack of teamwork and insufficient use of treatment limitation plans are not infrequent. 10, 27, 28 
Education in acute care
Several studies show that medical and nursing staff lack knowledge and skills in acute care, [29] [30] [31] [32] [33] [34] [35] [36] [37] e.g. oxygen therapy, 30 fluid and electrolyte balance, 31 analgesia, 32 issues of consent, 33 pulse oximetry, 30, 34, 35 and drug doses. 36 Staff education is an essential part of implementing a system to prevent cardiac arrest but to date, randomised controlled studies addressing the impact of specific educational interventions are lacking. 37 In one study, virtually all the improvement in the hospital cardiac arrest rate occurred during the educational phase of implementation of a medical emergency team (MET) system. 38, 39 Rapid response teams, such as METs, play a role in educating and improving acute care skills of ward personnel. 37, 40 The introduction of specific, objective calling criteria, 41 referral tools 42 and feedback to caregivers 43 has resulted in improved MET use and a significant reduction in cardiac arrests. Another study found that the number of cardiac arrest calls decreased while pre-arrest calls increased after implementing a standardised educational programme 44 in two hospitals 45 ; this was associated with a decrease in CA incidence and improved CA survival. Other research suggests that multiprofessional education did not alter the rate of mortality or staff awareness of patients at risk on general wards. 46 
Monitoring and recognition of the critically ill patient
Clinical signs of acute illness are similar whatever the underlying process, as they reflect failing respiratory, cardiovascular and neurological systems. Alterations in physiological variables, singly or in combination are associated with, or can be used to predict the occurrence of cardiac arrest, 12, [47] [48] [49] [50] hospital death 20, 21, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] and unplanned ICU admission, 47, 66, 69, 70 and with increasing magnitude and number of derangements the likelihood of death is increased. 18, 47, 48, 63, [71] [72] [73] [74] [75] [76] [77] [78] [79] Even though abnormal physiology is common on general wards, 80 the measurement and documentation of vital signs is suboptimal. 9, 11, 22, 49, [81] [82] [83] To assist in the early detection of critical illness, each patient should have a documented plan for vital signs monitoring including which physiological measurements needs no be undertaken and frequency. 24, 84 Many hospitals use early warning scores (EWS) or calling criteria to identify ward patients needing escalation of care, 22, 49, 82, [85] [86] [87] [88] [89] and this increases vital signs monitoring. 82, 88, 89 These calling criteria or 'track and trigger' systems include single-parameter systems, multiple-parameter systems, aggregate weighted scoring systems or combination systems. 90 Aggregate weighted track and trigger systems offer a graded escalation of care, whereas single parameter track and trigger systems provide an all-or-nothing response. Simpler systems may have advantages over more complex ones. 91, 92 Nurse concern may also be an important predictor of patient deterioration. [93] [94] [95] The use of an aggregate score based on a number of vital sign abnormalities appears more important than abnormalities in a single criteria. 96, 97 Aggregate-weighted scoring systems vary in their performance and in which endpoint they predict. 20, 70, 98 In older (>65 year) patients, who represent the largest group of IHCA patients, 99 signs of deterioration before cardiac arrest are often blunted, and the predictive value of the Modified Early Warning Score (MEWS) progressively decreases with increasing patient age. 100 The design of vital signs charts 19, 101 or the use of technology [102] [103] [104] may have an important role in the detection of deterioration and the escalation of care, but these require further study. Possible benefits include increased vital signs recording, 105 improved identification of signs of deterioration, 19, 101, 104 reduced time to team activation 103 and improved patient outcomes. 103, 106 Calling for help and the response to critical illness Nursing staff and junior doctors often find it difficult to ask for help or escalate treatment as they feel their clinical judgement may be criticised. [107] [108] [109] [110] In addition, there is a common belief, especially amongst younger staff, that the patient's primary team should be capable of dealing with problems close to their area of specialty. 110 It is logical that hospitals should ensure all staff are empowered to call for help and also trained to use structured communication tools such as RSVP (reason-story-vital signs-plan) 111 or SBAR (situation-background-assessment-recommendation) 112 tools to ensure effective inter-professional communication. However, recent research suggests that structured communication tools are rarely used in clinical practice. 113 The response to patients who are critically ill or who are at risk of becoming critically ill is now usually provided by a medical emergency team (MET), rapid response team (RRT), or critical care outreach team (CCOT). [114] [115] [116] [117] These replace or coexist with traditional cardiac arrest teams, which typically respond to patients already in cardiac arrest. MET/RRT usually comprise medical and nursing staff from intensive care and general medicine, who respond to specific calling criteria. Any member of the healthcare team can initiate a MET/RRT/CCOT call. In some hospitals, the patient, and their family and friends, are also encouraged to activate the team. [118] [119] [120] Team interventions often involve simple tasks such as starting oxygen therapy and intravenous fluids. [121] [122] [123] [124] [125] However, post-hoc analysis of the MERIT study data suggests that nearly all MET calls required 'critical care-type' interventions. 126 The MET, RRT or CCOT is often also involved in discussions regarding 'do not attempt cardiopulmonary resuscitation' (DNACPR) or end-of-life plans. [127] [128] [129] [130] [131] [132] [133] Recently, attempts have been made to develop a screening tool to identify patients at the end of life and quantify the risk of death in order to minimise prognostic uncertainty and avoid potentially harmful and futile treatments. 134 Studying the effect of the MET/RRT/CCOT systems on patient outcomes is difficult because of the complex nature of the intervention. During the period of most studies of rapid response teams, there has been a major international focus on improving other aspects of patient safety, e.g. hospital acquired infections, earlier treatment of sepsis and better medication management, all of which have the potential to influence patient deterioration and may have a beneficial impact on reducing cardiac arrests and hospital deaths. Most studies on RRT/MET systems to date originate from the USA and Australia and the systems effectiveness in other health care systems in not clear. 135 A well-designed, cluster-randomised controlled trial of the MET system (MERIT study) involving 23 hospitals 22 did not show a reduction in cardiac arrest rate after introduction of a MET when analysed on an intention-to-treat basis. Both the control and MET groups demonstrated improved outcome compared to baseline. Post hoc analysis of the MERIT study showed there was a decrease in cardiac arrest and unexpected mortality rate with increased activation of the MET system. 136 The evidence from predominantly single centre observational studies is inconclusive, with some studies showing reduced numbers of cardiac arrests after MET/RRT implementation 38, 41, 123, and some studies failing to show a reduction 121, 122, 124, 125, [160] [161] [162] [163] . However, systematic reviews, metaanalyses and multicentre studies do suggest that RRT/MET systems reduce rates of cardiopulmonary arrest and lower hospital mortality rates. [164] [165] [166] Concern has been expressed about MET activity leading to potential adverse events resulting from staff leaving normal duties to attend MET calls. Research suggests that although MET calls may cause disruption to normal hospital routines and inconvenience to staff, no major patient harm follows. 167 
Appropriate placement of patients
Ideally, the sickest patients should be admitted to an area that can provide the greatest supervision and the highest level of organ support and nursing care. International organisations have offered definitions of levels of care and produced admission and discharge criteria for high dependency units (HDUs) and ICUs. 168, 169 Staffing levels
Hospital staffing tends to be at its lowest during the night and at weekends, which may influence patient monitoring, treatment and outcome. Data from the US National Registry of CPR Investigators shows that survival rates from in-hospital cardiac arrest are lower during nights and weekends. 170 Outcomes for patients admitted to hospital and those discharged from the ICU are worse after hours and at weekends. [171] [172] [173] [174] Studies show that higher nurse staffing is associated with lower rates of failure-to-rescue, and reductions in rates of cardiac arrest rates, pneumonia, shock and death. 23, [175] [176] [177] 
Resuscitation decisions
The decision to start, continue and terminate resuscitation efforts is based on the balance between the risks, benefits and burdens these interventions place on patients, family members and healthcare providers. There are circumstances where resuscitation is inappropriate and should not be provided. Consider a 'do not attempt cardiopulmonary resuscitation' (DNACPR) decision when the patient:
• does not wish to have CPR • is very unlikely to survive cardiac arrest even if CPR is attempted.
There is wide variation in DNACPR decision-making practice throughout Europe particularly with respect to involvement of patients in decision-making. [178] [179] [180] [181] Improved knowledge, training and DNACPR decision-making should improve patient care and prevent futile CPR attempts. 182, 183 The section on ethics in the ERC Guidelines provides further information. 184 Guidelines for prevention of in-hospital cardiac arrest Hospitals should provide a system of care that includes: (a) staff education regarding the signs of patient deterioration and the rationale for rapid response to illness, (b) appropriate, and frequent monitoring of patients' vital signs, (c) clear guidance (e.g. via calling criteria or early warning scores) to assist staff in the early detection of patient deterioration, (d) a clear, uniform system of calling for assistance, and (e) an appropriate and timely clinical response to calls for help. 8 The following strategies may prevent avoidable in-hospital cardiac arrests:
(1) Provide care for patients who are critically ill or at risk of clinical deterioration in appropriate areas, with the level of care provided matched to the level of patient sickness. (2) Critically ill patients need regular observations: each patient should have a documented plan for vital signs monitoring that identifies which variables need to be measured and the frequency of measurement. Frequency of measurement should relate to the patient's severity of illness, and the likelihood of clinical deterioration and cardiopulmonary arrest. 
Prevention of sudden cardiac death (SCD) out-of-hospital
Coronary artery disease is the commonest cause of SCD. Nonischaemic cardiomyopathy and valvular disease account for most other SCD events in older people. Inherited abnormalities (e.g. Brugada syndrome, hypertrophic cardiomyopathy), congenital heart disease, myocarditis and substance abuse are predominant causes in the young.
Most SCD victims have a history of cardiac disease and warning signs, most commonly chest pain, in the hour before cardiac arrest. 185 In patients with a known diagnosis of cardiac disease, syncope (with or without prodrome -particularly recent or recurrent) is an independent risk factor for increased risk of death. [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] Chest pain on exertion only, and palpitations associated with syncope only, are associated with hypertrophic cardiomyopathy, coronary abnormalities, Wolff-Parkinson-White, and arrhythmogenic right ventricular cardiomyopathy.
Apparently healthy children and young adults who suffer SCD can also have signs and symptoms (e.g. syncope/pre-syncope, chest pain and palpitations) that should alert healthcare professionals to seek expert help to prevent cardiac arrest. [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] Children and young adults presenting with characteristic symptoms of arrhythmic syncope should have a specialist cardiology assessment, which should include an ECG and in most cases an echocardiogram and exercise test. Characteristics of arrhythmic syncope include: syncope in the supine position, occurring during or after exercise, with no or only brief prodromal symptoms, repetitive episodes, or in individuals with a family history of sudden death. In addition, non-pleuritic chest pain, palpitations associated with syncope, seizures (when resistant to treatment, occurring at night or precipitated by exercise, syncope, or loud noise) and drowning in a competent swimmer should raise suspicion of increased risk. Systematic evaluation in a clinic specialising in the care of those at risk for SCD is recommended in family members of young victims of SCD or those with a known cardiac disorder resulting in an increased risk of SCD. 186, [207] [208] [209] [210] [211] A family history of syncope or SCD, palpitations as a symptom, supine syncope and syncope associated with exercise and emotional stress are more common in patients with long QT syndrome (LQTS). 212 In older adults 213, 214 the absence of nausea and vomiting before syncope and ECG abnormalities is an independent predictor of arrhythmic syncope.
Inexplicable drowning and drowning in a strong swimmer may be due to LQTS or catecholaminergic polymorphic ventricular tachycardia (CPVT). 215 There is an association between LQTS and presentation with seizure phenotype. 216, 217 Guidance has been published for the screening of those at risk of sudden death including the screening of athletes. Screening programmes for athletes vary between countries. 218, 219 Identification of individuals with inherited conditions and screening of family members can help prevent deaths in young people with inherited heart disorders. [220] [221] [222] 
3b -Prehospital resuscitation
This section provides an overview of prehospital resuscitation. Many of the specific issues about prehospital resuscitation are addressed in sections covering ALS interventions, or are generic for both resuscitation for in-hospital and out-of-hospital cardiac arrest. 223 Adult BLS and automated external defibrillation contains guidance on the techniques used during the initial resuscitation of an adult cardiac arrest victim. In addition, many of the specific situations associated with cardiac arrest that are encountered in prehospital resuscitation are addressed in Section 4 -cardiac arrest in special circumstances. 224 
EMS personnel and interventions
There is considerable variation across Europe in the structure and process of emergency medical services (EMS) systems. Some countries have adopted almost exclusively paramedic/emergency medical technician (EMT)-based systems while other incorporate prehospital physicians to a greater or lesser extent. Although some studies have documented higher survival rates after cardiac arrest in EMS systems that include experienced physicians, [225] [226] [227] [228] [229] [230] [231] [232] compared with those that rely on non-physician providers, 225, 226, 233, 234 some other comparisons have found no difference in survival between systems using paramedics or physicians as part of the response. [235] [236] [237] Well-organised non-physician systems with highly trained paramedics have also reported high survival rates. 238 Given the inconsistent evidence, the inclusion or exclusion of physicians among prehospital personnel responding to cardiac arrests will depend largely on existing local policy.
Whether ALS interventions by EMS improve outcomes is also uncertain. A meta-analysis suggested that ALS care can increase survival in non-traumatic OHCA. 239 However, a recent large observational study using propensity matching showed survival to hospital discharge and 90 day survival was greater among patients receiving BLS. 240 It is not possible to say whether this is a true difference or the result of unmeasured confounders.
CPR versus defibrillation first for out-of-hospital cardiac arrest
There is evidence that performing chest compressions while retrieving and charging a defibrillator improves the probability of survival. 241 One randomised controlled trial (RCT) 242 found increased ROSC, discharge-and one-year survival in patients with longer arrest times (>5 min). However, we have to keep in mind that this, and a large before-after study from Seattle 243 that showed better outcomes with 90 s of CPR before a shock when the response interval was >4 min), are from a time when 3 stacked-shocks were used and shorter periods of CPR between shocks (1 min). Evidence from five RCTs 242,244-247 and another study 248 suggests that among unmonitored patients with OHCA and an initial rhythm of VF/pVT, there is no benefit in a period of CPR of 90-180 s before defibrillation when compared with immediate defibrillation with CPR being performed while the defibrillator equipment is being applied.
A sub-analysis in one RCT 245 showed no difference in survival to hospital discharge with a prolonged period of CPR (180 s) and delayed defibrillation in patients with a shockable initial rhythm who received bystander CPR. Yet, for those EMS agencies with a higher baseline survival to hospital discharge (defined as >20% for an initial shockable rhythm), 180 s of CPR prior to defibrillation was more beneficial compared with a shorter period of CPR (30-60 s) .
EMS personnel should provide high-quality CPR while a defibrillator is retrieved, applied and charged. Defibrillation should not be delayed longer than needed to establish the need for defibrillation and charging. The routine delivery of a pre-specified period of CPR (e.g. 2 or 3 min) before rhythm analysis and a shock is delivered is not recommended.
Termination of resuscitation rules
The 'basic life support termination of resuscitation rule' is predictive of death when applied by defibrillation-only emergency medical technicians. 249 The rule recommends termination when there is no ROSC, no shocks are administered and EMS personnel do not witness the arrest. Several studies have shown external generalisability of this rule. [250] [251] [252] [253] [254] [255] [256] More recent studies show that EMS systems providing ALS interventions can also use this BLS rule and therefore termed it the 'universal' termination of resuscitation rule. 251, 257, 258 Additional studies have shown associations with futility of certain variables such as no ROSC at scene; non-shockable rhythm; unwitnessed arrest; no bystander CPR, call response time and patient demographics. [259] [260] [261] [262] [263] [264] [265] [266] [267] Termination of resuscitation rules for in-hospital cardiac arrest are less reliable although EMS rules may be useful for those with out-of-hospital cardiac arrest who have ongoing resuscitation in the emergency department. [268] [269] [270] [271] Prospectively validated termination of resuscitation rules can be used to guide termination of prehospital CPR in adults; however, these must be validated in an EMS system similar to the one in which implementation is proposed. Termination of resuscitation rules may require integration with guidance on suitability for extracorporeal CPR (eCPR) or organ donation. 272 Organ donation is specifically addressed in Section 5 -Post-resuscitation care. 273, 274 3c -In-hospital resuscitation After in-hospital cardiac arrest, the division between BLS and ALS is arbitrary; in practice, the resuscitation process is a continuum and is based on common sense. The public expect that clinical staff can undertake cardiopulmonary resuscitation (CPR). For all in-hospital cardiac arrests, ensure that:
• cardiorespiratory arrest is recognised immediately; • help is summoned using a standard telephone number;
• CPR is started immediately using airway adjuncts, e.g. a bag mask and, if indicated, defibrillation attempted as rapidly as possible and certainly within 3 min.
The exact sequence of actions after in-hospital cardiac arrest will depend on many factors, including:
• location (clinical/non-clinical area; monitored/unmonitored area); • training of the first responders;
• number of responders;
• equipment available;
• hospital response system to cardiac arrest and medical emergencies, (e.g. MET, RRT).
Location
Patients who have monitored arrests are usually diagnosed rapidly. Ward patients may have had a period of deterioration and an unwitnessed arrest. 9, 11 Ideally, all patients who are at high risk of cardiac arrest should be cared for in a monitored area where facilities for immediate resuscitation are available.
Training of first responders
All healthcare professionals should be able to recognise cardiac arrest, call for help and start CPR. Staff should do what they have been trained to do. For example, staff in critical care and emergency medicine will have more advanced resuscitation skills than staff who are not involved regularly in resuscitation in their normal clinical role. Hospital staff who attend a cardiac arrest may have different levels of skill to manage the airway, breathing and circulation. Rescuers must undertake only the skills in which they are trained and competent.
Number of responders
The single responder must ensure that help is coming. If other staff are nearby, several actions can be undertaken simultaneously.
Equipment available
All clinical areas should have immediate access to resuscitation equipment and drugs to facilitate rapid resuscitation of the patient in cardiopulmonary arrest. Ideally, the equipment used for CPR (including defibrillators) and the layout of equipment and drugs should be standardised throughout the hospital. [275] [276] [277] Equipment should be checked regularly, e.g. daily, to ensure its readiness for use in an emergency.
Resuscitation team
The resuscitation team may take the form of a traditional cardiac arrest team, which is called only when cardiac arrest is recognised. Alternatively, hospitals may have strategies to recognise patients at risk of cardiac arrest and summon a team (e.g. MET or RRT) before cardiac arrest occurs. The term 'resuscitation team' reflects the range of response teams. In hospital cardiac arrests are rarely sudden or unexpected. A strategy of recognising patients at risk of cardiac arrest may enable some of these arrests to be prevented, or In-hospital resuscitation algorithm. ABCDE -Airway, Breathing Circulation, Disability, Exposure; IV -intravenous; CPR -cardiopulmonary resuscitation may prevent futile resuscitation attempts in those who are unlikely to benefit from CPR.
Immediate actions for a collapsed patient in a hospital
An algorithm for the initial management of in-hospital cardiac arrest is shown in Fig. 3 .1.
• Ensure personal safety.
• When healthcare professionals see a patient collapse or find a patient apparently unconscious in a clinical area, they should first summon help (e.g. emergency bell, shout), then assess if the patient is responsive. Gently shake the shoulders and ask loudly: 'Are you all right?' • If other members of staff are nearby, it will be possible to undertake actions simultaneously.
The responsive patient Urgent medical assessment is required. Depending on the local protocols, this may take the form of a resuscitation team (e.g. MET, RRT). While awaiting this team, give oxygen, attach monitoring and insert an intravenous cannula.
The unresponsive patient
The exact sequence will depend on the training of staff and experience in assessment of breathing and circulation. Trained healthcare staff cannot assess the breathing and pulse sufficiently reliably to confirm cardiac arrest. [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] Agonal breathing (occasional gasps, slow, laboured or noisy breathing) is common in the early stages of cardiac arrest and is a sign of cardiac arrest and should not be confused as a sign of life. [288] [289] [290] [291] Agonal breathing can also occur during chest compressions as cerebral perfusion improves, but is not indicative of ROSC. Cardiac arrest can cause an initial short seizure-like episode that can be confused with epilepsy. 292, 293 Finally changes in skin colour, notably pallor and bluish changes associated with cyanosis are not diagnostic of cardiac arrest. 292 • Shout for help (if not already) • Turn the victim on to his back and then open the airway:
• Open airway and check breathing:
• Open the airway using a head tilt chin lift • Keeping the airway open, look, listen and feel for normal breathing (an occasional gasp, slow, laboured or noisy breathing is not normal):
• Look for chest movement • Listen at the victim's mouth for breath sounds • Feel for air on your cheek • Look, listen and feel for no more than 10 s to determine if the victim is breathing normally.
• Check for signs of a circulation:
• It may be difficult to be certain that there is no pulse. If the patient has no signs of life (consciousness, purposeful movement, normal breathing, or coughing), or if there is doubt, start CPR immediately until more experienced help arrives or the patient shows signs of life.
• Delivering chest compressions to a patient with a beating heart is unlikely to cause harm. 294 However, delays in diagnosing cardiac arrest and starting CPR will adversely effect survival and must be avoided.
• Only those experienced in ALS should try to assess the carotid pulse whilst simultaneously looking for signs of life. This rapid assessment should take no more than 10 s. Start CPR if there is any doubt about the presence or absence of a pulse.
• If there are signs of life, urgent medical assessment is required.
Depending on the local protocols, this may take the form of a resuscitation team. While awaiting this team, give the patient oxygen, attach monitoring and insert an intravenous cannula. When a reliable measurement of oxygen saturation of arterial blood (e.g. pulse oximetry (SpO 2 )) can be achieved, titrate the inspired oxygen concentration to achieve a SpO 2 of 94-98%.
• If there is no breathing, but there is a pulse (respiratory arrest), ventilate the patient's lungs and check for a circulation every 10 breaths. Start CPR if there is any doubt about the presence or absence of a pulse.
Starting in-hospital CPR
The key steps are listed here. Supporting evidence can be found in the sections on specific interventions that follow.
• One person starts CPR as others call the resuscitation team and collect the resuscitation equipment and a defibrillator. If only one member of staff is present, this will mean leaving the patient.
• Give 30 chest compressions followed by 2 ventilations.
• Compress to a depth of at least 5 cm but not more than 6 cm.
• Perform chest compressions should be performed at a rate of 100-120 min −1 .
• Allow the chest to recoil completely after each compression; do not lean on the chest.
• Minimise interruptions and ensure high-quality compressions.
• Undertaking high-quality chest compressions for a prolonged time is tiring; with minimal interruption, try to change the person doing chest compressions every 2 min.
• Maintain the airway and ventilate the lungs with the most appropriate equipment immediately to hand. Pocket mask ventilation or two-rescuer bag-mask ventilation, which can be supplemented with an oral airway, should be started. Alternatively, use a supraglottic airway device (SGA) and self-inflating bag. Tracheal intubation should be attempted only by those who are trained, competent and experienced in this skill.
• Waveform capnography must be used for confirming tracheal tube placement and monitoring ventilation rate. Waveform capnography can also be used with a bag-mask device and SGA. The further use of waveform capnography to monitor CPR quality and potentially identify ROSC during CPR is discussed later in this section. 295 • Use an inspiratory time of 1 s and give enough volume to produce a normal chest rise. Add supplemental oxygen to give the highest feasible inspired oxygen as soon as possible. 4 • Once the patient's trachea has been intubated or a SGA has been inserted, continue uninterrupted chest compressions (except for defibrillation or pulse checks when indicated) at a rate of 100-120 min 296 Pause briefly to assess the heart rhythm. With a manual defibrillator, if the rhythm is VF/pVT charge the defibrillator while another rescuer continues chest compressions. Once the defibrillator is charged, pause the chest compressions and then give one shock, and immediately resume chest compressions. Ensure no one is touching the patient during shock delivery. Plan and ensure safe defibrillation before the planned pause in chest compressions.
• If using an automated external defibrillator (AED) follow the AED's audio-visual prompts, and similarly aim to minimise pauses in chest compressions by rapidly following prompts.
• The ALS Writing Group recognises that in some settings where self-adhesive defibrillation pads are not available, alternative defibrillation strategies using paddles are used to minimise the preshock pause.
• The ALS writing group is aware that in some countries a defibrillation strategy that involves charging the defibrillator towards the end of every 2 min cycle of CPR in preparation for the pulse check is used. 297, 298 If the rhythm is VF/pVT a shock is given and CPR resumed. Whether this leads to any benefit is unknown, but it does lead to defibrillator charging for non-shockable rhythms.
• Restart chest compressions immediately after the defibrillation attempt. Minimise interruptions to chest compressions. When using a manual defibrillator it is possible to reduce the pause between stopping and restarting of chest compressions to less than 5 s.
• Continue resuscitation until the resuscitation team arrives or the patient shows signs of life. Follow the voice prompts if using an AED.
• Once resuscitation is underway, and if there are sufficient staff present, prepare intravenous cannulae and drugs likely to be used by the resuscitation team (e.g. adrenaline).
• Identify one person to be responsible for handover to the resuscitation team leader. Use a structured communication tool for handover (e.g. SBAR, RSVP). 111, 112 Locate the patient's records.
• The quality of chest compressions during in-hospital CPR is frequently sub-optimal. 299, 300 The importance of uninterrupted chest compressions cannot be over emphasised. Even short interruptions to chest compressions are disastrous for outcome and every effort must be made to ensure that continuous, effective chest compression is maintained throughout the resuscitation attempt. Chest compressions should commence at the beginning of a resuscitation attempt and continue uninterrupted unless they are paused briefly for a specific intervention (e.g. rhythm check). Most interventions can be performed without interruptions to chest compressions. The team leader should monitor the quality of CPR and alternate CPR providers if the quality of CPR is poor.
• Continuous ETCO 2 monitoring during CPR can be used to indicate the quality of CPR, and a rise in ETCO 2 can be an indicator of ROSC during chest compressions. 295, [301] [302] [303] • If possible, the person providing chest compressions should be changed every 2 min, but without pauses in chest compressions.
3d -ALS treatment algorithm

Introduction
Heart rhythms associated with cardiac arrest are divided into two groups: shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT)) and non-shockable rhythms (asystole and pulseless electrical activity (PEA)). The principal difference in the treatment of these two groups of arrhythmias is the need for attempted defibrillation in those patients with VF/pVT. Other interventions, including high-quality chest compressions with minimal interruptions, airway management and ventilation, venous access, administration of adrenaline and the identification and correction of reversible causes, are common to both groups.
Although the ALS cardiac arrest algorithm ( Fig. 3.2 ) is applicable to all cardiac arrests, additional interventions may be indicated for cardiac arrest caused by special circumstances (see Section 4). 224 The interventions that unquestionably contribute to improved survival after cardiac arrest are prompt and effective bystander basic life support (BLS), uninterrupted, high-quality chest compressions and early defibrillation for VF/pVT. The use of adrenaline has been shown to increase ROSC but not survival to discharge. Furthermore there is a possibility that it causes worse long-term neurological survival. Similarly, the evidence to support the use of advanced airway interventions during ALS remains limited. 4, [304] [305] [306] [307] [308] [309] [310] [311] Thus, although drugs and advanced airways are still included among ALS interventions, they are of secondary importance to early defibrillation and high-quality, uninterrupted chest compressions. As an indicator of equipoise for many ALS interventions at the time of writing these guidelines, three large RCTs (adrenaline versus placebo [ISRCTN73485024], amiodarone versus lidocaine versus placebo 312 [NCT01401647] and SGA versus tracheal intubation [ISRCTN No: 08256118]) are currently ongoing.
As with previous guidelines, the ALS algorithm distinguishes between shockable and non-shockable rhythms. Each cycle is broadly similar, with a total of 2 min of CPR being given before assessing the rhythm and where indicated, feeling for a pulse. Adrenaline 1 mg is injected every 3-5 min until ROSC is achieved -the timing of the initial dose of adrenaline is described below. In VF/pVT, a single dose of amiodarone 300 mg is indicated after a total of three shocks and a further dose of 150 mg can be considered after five shocks. The optimal CPR cycle time is not known and algorithms for longer cycles (3 min) exist which include different timings for adrenaline doses. 313 
Duration of resuscitation attempt
The duration of any individual resuscitation attempt should be based on the individual circumstances of the case and is a matter of clinical judgement, taking into consideration the circumstances and the perceived prospect of a successful outcome. If it was considered appropriate to start resuscitation, it is usually considered worthwhile continuing, as long as the patient remains in VF/pVT, or there is a potentially reversible cause than can be treated. The use of mechanical compression devices and extracorporeal CPR techniques make prolonged attempts at resuscitation feasible in selected patients.
In a large observational study of patients with IHCA, the median duration of resuscitation was 12 min (IQR 6-21 min) in those with ROSC compared with 20 min (IQR 14-30 min) for those with no ROSC. 314 Hospitals with the longest resuscitation attempts (median 25 min [IQR 25-28 min]) had a higher risk-adjusted rate of ROSC and survival to discharge compared with a shorter median duration of resuscitation attempt. 314, 315 It is generally accepted that asystole for more than 20 min in the absence of a reversible cause and with ongoing ALS constitutes a reasonable ground for stopping further resuscitation attempts. 316 The ethical principles of starting and stopping CPR are addressed in Section 11, the Ethics of resuscitation and end-of-life decisions. 184 Shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia)
The first monitored rhythm is VF/pVT in approximately 20% both for in-hospital 317, 7, 318, 319 and out-of-hospital cardiac arrests. 320 The incidence of VF/pVT may be decreasing, [321] [322] [323] [324] and can vary according to bystander CPR rates. Ventricular fibrillation/pulseless ventricular tachycardia will also occur at some stage during resuscitation in about 25% of cardiac arrests with an initial documented rhythm of asystole or PEA. 317, 325 Having confirmed cardiac arrest, summon help (including the request for a defibrillator) and start CPR, beginning with chest compressions, with a compression: ventilation (CV) ratio of 30:2. When the defibrillator arrives, continue chest compressions while applying the defibrillation electrodes. Identify the rhythm and treat according to the ALS algorithm.
• If VF/pVT is confirmed, charge the defibrillator while another rescuer continues chest compressions. Once the defibrillator is charged, pause the chest compressions, quickly ensure that all rescuers are clear of the patient and then give one shock.
• Defibrillation shock energy levels are unchanged from the 2010 guidelines. 2 For biphasic waveforms (rectilinear biphasic or biphasic truncated exponential), use an initial shock energy of at least 150 J. For pulsed biphasic waveforms, begin at 120-150 J. The shock energy for a particular defibrillator should be based on the manufacturer's guidance. It is important that those using manual defibrillators are aware of the appropriate energy settings for the type of device used. Manufacturers should consider labelling their manual defibrillators with energy level instructions, but in the absence of this and if appropriate energy levels are unknown, for adults use the highest available shock energy for all shocks. With manual defibrillators it is appropriate to consider escalating the shock energy if feasible, after a failed shock and for patients where refibrillation occurs. 326, 327 • Minimise the delay between stopping chest compressions and delivery of the shock (the preshock pause); even a 5-10 s delay will reduce the chances of the shock being successful. [328] [329] [330] [331] • Without pausing to reassess the rhythm or feel for a pulse, resume CPR (CV ratio 30:2) immediately after the shock, starting with chest compressions to limit the post-shock pause and the total peri-shock pause. 330, 331 Even if the defibrillation attempt is successful in restoring a perfusing rhythm, it takes time to establish a post shock circulation 332 and it is very rare for a pulse to be palpable immediately after defibrillation. 333 In one study, after defibrillation attempts, most patients having ALS remained pulseless for over 2 min and the duration of asystole before ROSC was longer than 2 min beyond the shock in as many as 25%. 334 If a shock has been successful immediate resumption of chest compressions does not increase the risk of VF recurrence. 335 Furthermore, the delay in trying to palpate a pulse will further compromise the myocardium if a perfusing rhythm has not been restored. 336 • Continue CPR for 2 min, then pause briefly to assess the rhythm; if still VF/pVT, give a second shock (150-360 J biphasic). Without pausing to reassess the rhythm or feel for a pulse, resume CPR (CV ratio 30:2) immediately after the shock, starting with chest compressions.
• Continue CPR for 2 min, then pause briefly to assess the rhythm; if still VF/pVT, give a third shock (150-360 J biphasic). Without reassessing the rhythm or feeling for a pulse, resume CPR (CV ratio 30:2) immediately after the shock, starting with chest compressions.
• If IV/IO access has been obtained, during the next 2 min of CPR give adrenaline 1 mg and amiodarone 300 mg. 337 • The use of waveform capnography may enable ROSC to be detected without pausing chest compressions and may be used as a way of avoiding a bolus injection of adrenaline after ROSC has been achieved. Several human studies have shown that there is a significant increase in end-tidal CO 2 when ROSC occurs. 295, [301] [302] [303] 338, 339 If ROSC is suspected during CPR withhold adrenaline. Give adrenaline if cardiac arrest is confirmed at the next rhythm check.
• If ROSC has not been achieved with this 3rd shock, the adrenaline may improve myocardial blood flow and increase the chance of successful defibrillation with the next shock. In animal studies, peak plasma concentrations of adrenaline occur at about 90 s after a peripheral injection and the maximum effect on coronary perfusion pressure is achieved around the same time (70 s). 340 Importantly, high-quality chest compressions are needed to circulate the drug to achieve these times.
• Timing of adrenaline dosing can cause confusion amongst ALS providers and this aspect needs to be emphasised during training. 341 During treatment of VF/pVT, healthcare providers must practice efficient coordination between CPR and shock delivery whether using a manual defibrillator or an AED. When VF is present for more than a few minutes, the myocardium is depleted of oxygen and metabolic substrates. A brief period of chest compressions will deliver oxygen and energy substrates and increase the probability of restoring a perfusing rhythm after shock delivery. 342 Analyses of VF waveform characteristics predictive of shock success indicate that the shorter the time between chest compression and shock delivery, the more likely the shock will be successful. 342, 343 Reduction in the peri-shock pause (the interval between stopping compressions to resuming compressions after shock delivery) by even a few seconds can increase the probability of shock success. [328] [329] [330] [331] Moreover, continuing high-quality CPR however may improve the amplitude and frequency of the VF and improve the chance of successful defibrillation to a perfusing rhythm. [344] [345] [346] Regardless of the arrest rhythm, after the initial adrenaline dose has been given, give further doses of adrenaline 1 mg every 3-5 min until ROSC is achieved; in practice, this will be about once every two cycles of the algorithm. If signs of life return during CPR (purposeful movement, normal breathing or coughing), or there is an increase in ETCO 2 , check the monitor; if an organised rhythm is present, check for a pulse. If a pulse is palpable, start post-resuscitation care. If no pulse is present, continue CPR.
Witnessed, monitored VF/pVT
If a patient has a monitored and witnessed cardiac arrest in the catheter laboratory, coronary care unit, a critical care area or whilst monitored after cardiac surgery, and a manual defibrillator is rapidly available:
• Confirm cardiac arrest and shout for help.
• If the initial rhythm is VF/pVT, give up to three quick successive (stacked) shocks.
• Rapidly check for a rhythm change and, if appropriate, ROSC after each defibrillation attempt.
• Start chest compressions and continue CPR for 2 min if the third shock is unsuccessful.
This three-shock strategy may also be considered for an initial, witnessed VF/pVT cardiac arrest if the patient is already connected to a manual defibrillator. Although there are no data supporting a three-shock strategy in any of these circumstances, it is unlikely that chest compressions will improve the already very high chance of ROSC when defibrillation occurs early in the electrical phase, immediately after onset of VF.
If this initial three-shock strategy is unsuccessful for a monitored VF/pVT cardiac arrest, the ALS algorithm should be followed and these three-shocks treated as if only the first single shock has been given.
The first dose of adrenaline should be given after another 2 shock attempts if VF persists, i.e. Give 3 shocks, then 2 min CPR, then shock attempt, then 2 min CPR, then shock attempt, and then consider adrenaline during this 2 min of CPR. We recommend amiodarone is given after three defibrillation attempts irrespective of whether they are consecutive shocks, or interrupted by CPR and non-shockable rhythms.
Specific guidance concerning the need for resternotomy, and drug timing if the initial stacked shocks are unsuccessful when cardiac arrest occurs after cardiac surgery is addressed in Section 4 -cardiac arrest in special circumstances. 224 
Persistent ventricular fibrillation/pulseless ventricular tachycardia
In VF/pVT persists, consider changing the position of the pads/paddles. 2 Review all potentially reversible causes using the 4 H and 4 T approach (see below) and treat any that are identified. Persistent VF/pVT may be an indication for percutaneous coronary intervention (PCI) -in these cases, a mechanical chest compression device can be used to maintain high-quality chest compressions for transport and PCI. 347 The use of extracorporeal CPR (see below) should also be considered to support the circulation whilst a reversible cause it treated.
Precordial thump
A single precordial thump has a very low success rate for cardioversion of a shockable rhythm. [348] [349] [350] [351] [352] Its routine use is therefore not recommended. It may be appropriate therapy only when used without delay whilst awaiting the arrival of a defibrillator in a monitored VF/pVT arrest. 353 Using the ulnar edge of a tightly clenched fist, deliver a sharp impact to the lower half of the sternum from a height of about 20 cm, then retract the fist immediately to create an impulse-like stimulus. There are rare reports of a precordial thump converting a perfusing to a non-perfusing rhythm. 354 
Airway and ventilation
During the treatment of persistent VF, ensure good-quality chest compressions between defibrillation attempts. Consider reversible causes (4 Hs and 4 Ts) and, if identified, correct them. Tracheal intubation provides the most reliable airway, but should be attempted only if the healthcare provider is properly trained and has regular, ongoing experience with the technique. Tracheal intubation must not delay defibrillation attempts. Personnel skilled in advanced airway management should attempt laryngoscopy and intubation without stopping chest compressions; a brief pause in chest compressions may be required as the tube is passed through the vocal cords, but this pause should be less than 5 s. Alternatively, to avoid any interruptions in chest compressions, the intubation attempt may be deferred until ROSC. No RCTs have shown that tracheal intubation increases survival after cardiac arrest. After intubation, confirm correct tube position and secure it adequately. Ventilate the lungs at 10 breaths min −1 ; do not hyperventilate the patient. Once the patient's trachea has been intubated, continue chest compressions, at a rate of 100-120 min −1 without pausing during ventilation. A pause in the chest compressions causes the coronary perfusion pressure to fall substantially. On resuming compressions, there is some delay before the original coronary perfusion pressure is restored, thus chest compressions that are not interrupted for ventilation (or any reason) result in a substantially higher mean coronary perfusion pressure.
In the absence of personnel skilled in tracheal intubation, a supraglottic airway (SGA) (e.g. laryngeal mask airway, laryngeal tube or i-gel) is an acceptable alternative. Once a SGA has been inserted, attempt to deliver continuous chest compressions, uninterrupted by ventilation. 355 If excessive gas leakage causes inadequate ventilation of the patient's lungs, chest compressions will have to be interrupted to enable ventilation (using a CV ratio of 30:2). Airway interventions for cardiac arrest and the evidence supporting them are described in Section 3f.
Intravenous access and drugs
Peripheral versus central venous drug delivery. Establish intravenous access if this has not already been achieved. Although peak drug concentrations are higher and circulation times are shorter when drugs are injected into a central venous catheter compared with a peripheral cannula, 356 insertion of a central venous catheter requires interruption of CPR and can be technically challenging and associated with complications. Peripheral venous cannulation is quicker, easier to perform and safer. Drugs injected peripherally must be followed by a flush of at least 20 ml of fluid and elevation of the extremity for 10-20 s to facilitate drug delivery to the central circulation.
Intraosseous route. If intravenous access is difficult or impossible, consider the IO route. This is now established as an effective route in adults. [357] [358] [359] [360] [361] [362] [363] [364] [365] Intraosseous injection of drugs achieves adequate plasma concentrations in a time comparable with injection through a vein. 366, 367 Animal studies suggest that adrenaline reaches a higher concentration and more quickly when it is given intravenously as compared with the intraosseous route, and that the sternal intraosseous route more closely approaches the pharmacokinetic of IV adrenaline. 368 The recent availability of mechanical IO devices has increased the ease of performing this technique. 369 There are a number of intraosseous devices available as well as a choice of insertion sites including the humerus, proximal or distal tibia, and sternum. We have not done a formal review of devices or insertion sites as part of the 2015 Guidelines process. The decision concerning choice of device and insertion site should be made locally and staff adequately trained in its use.
Adrenaline for initial VF/pVT arrest. On the basis of expert consensus, for VF/pVT give adrenaline after the third shock once chest compressions have resumed, and then repeat every 3-5 min during cardiac arrest (alternate cycles). Do not interrupt CPR to give drugs. The use of waveform capnography may enable ROSC to be detected without pausing chest compressions and may be used as a way of avoiding a bolus injection of adrenaline after ROSC has been achieved. If ROSC is suspected during CPR, withhold adrenaline and continue CPR. Give adrenaline if cardiac arrest is confirmed at the next rhythm check.
Despite the widespread use of adrenaline during resuscitation, there is no placebo-controlled study that shows that the routine use of any vasopressor at any stage during human cardiac arrest increases neurologically intact survival to hospital discharge.
Further information concerning the role of adrenaline in cardiac arrest is addressed in Section 3g -drugs and fluids during CPR.
Anti-arrhythmic drugs. We recommend that amiodarone should be given after three defibrillation attempts irrespective of whether they are consecutive shocks, or interrupted by CPR, or for recurrent VF/pVT during cardiac arrest. Give amiodarone 300 mg intravenously; a further dose of 150 mg may be given after five defibrillation attempts. Lidocaine 1 mg kg −1 may be used as an alternative if amiodarone is not available but do not give lidocaine if amiodarone has been given already. Further information concerning the role of amiodarone in cardiac arrest is addressed in Section 3g -drugs and fluid during CPR.
Non-shockable rhythms (PEA and asystole)
Pulseless electrical activity (PEA) is defined as cardiac arrest in the presence of electrical activity (other than ventricular tachyarrhythmia) that would normally be associated with a palpable pulse. 370 These patients often have some mechanical myocardial contractions, but these are too weak to produce a detectable pulse or blood pressure -this is sometimes described as 'pseudo-PEA' (see below). PEA is often caused by reversible conditions, and can be treated if those conditions are identified and corrected. Survival following cardiac arrest with asystole or PEA is unlikely unless a reversible cause can be found and treated effectively.
If the initial monitored rhythm is PEA or asystole, start CPR 30:2. If asystole is displayed, without stopping CPR, check that the leads are attached correctly. Once an advanced airway has been sited, continue chest compressions without pausing during ventilation. After 2 min of CPR, recheck the rhythm. If asystole is present, resume CPR immediately. If an organised rhythm is present, attempt to palpate a pulse. If no pulse is present (or if there is any doubt about the presence of a pulse), continue CPR.
Give adrenaline 1 mg as soon as venous or intraosseous access is achieved, and repeat every alternate CPR cycle (i.e. about every 3-5 min). If a pulse is present, begin post-resuscitation care. If signs of life return during CPR, check the rhythm and check for a pulse. If ROSC is suspected during CPR withhold adrenaline and continue CPR. Give adrenaline if cardiac arrest is confirmed at the next rhythm check.
Whenever a diagnosis of asystole is made, check the ECG carefully for the presence of P waves, because this may respond to cardiac pacing. There is no benefit in attempting to pace true asystole. In addition, if there is doubt about whether the rhythm is asystole or extremely fine VF, do not attempt defibrillation; instead, continue chest compressions and ventilation. Continuing highquality CPR however may improve the amplitude and frequency of the VF and improve the chance of successful defibrillation to a perfusing rhythm. [344] [345] [346] The optimal CPR time between rhythm checks may vary according to the cardiac arrest rhythm and whether it is the first or subsequent loop. 371 Based on expert consensus, for the treatment of asystole or PEA, following a 2-min cycle of CPR, if the rhythm has changed to VF, follow the algorithm for shockable rhythms. Otherwise, continue CPR and give adrenaline every 3-5 min following the failure to detect a palpable pulse with the pulse check. If VF is identified on the monitor midway through a 2-min cycle of CPR, complete the cycle of CPR before formal rhythm and shock delivery if appropriate -this strategy will minimise interruptions in chest compressions.
Potentially reversible causes
Potential causes or aggravating factors for which specific treatment exists must be considered during any cardiac arrest. For ease of memory, these are divided into two groups of four, based upon their initial letter: either H or T. More details on many of these conditions are covered in Section 4 -special circumstances. 224 The four 'Hs'
Minimise the risk of hypoxia by ensuring that the patient's lungs are ventilated adequately with the maximal possible inspired oxygen during CPR. Make sure there is adequate chest rise and bilateral breath sounds. Using the techniques described in Section 3f, check carefully that the tracheal tube is not misplaced in a bronchus or the oesophagus.
Pulseless electrical activity caused by hypovolaemia is due usually to severe haemorrhage. This may be precipitated by trauma (Section 4), 224 gastrointestinal bleeding or rupture of an aortic aneurysm. Intravascular volume should be restored rapidly with warmed fluid, coupled with urgent surgery to stop the haemorrhage.
Hyperkalaemia, hypokalaemia, hypocalcaemia, acidaemia and other metabolic disorders are detected by biochemical tests (usually by using a blood gas analyser) or suggested by the patient's medical history, e.g. renal failure (Section 4). 224 Intravenous calcium chloride is indicated in the presence of hyperkalaemia, hypocalcaemia and calcium channel-blocker overdose.
Hypothermia should be suspected based on the history such as cardiac arrest associated with drowning (Section 4). 224 The four 'Ts'
Coronary thrombosis associated with an acute coronary syndrome or ischaemic heart disease is the most common cause of sudden cardiac arrest. An acute coronary syndrome is usually diagnosed and treated after ROSC is achieved. If an acute coronary syndrome is suspected, and ROSC has not been achieved, urgent coronary angiography should be considered when feasible and if required percutaneous coronary intervention. Mechanical chest compression devices and extracorporeal CPR can help facilitate this.
The commonest cause of thromboembolic or mechanical circulatory obstruction is massive pulmonary embolism. The treatment of cardiac arrest with known or suspected pulmonary embolism is addressed in Section 4 including the role of fibrinolysis, surgical or mechanical thrombectomy and extracorporeal CPR. 224 A tension pneumothorax may be the primary cause of PEA and may be associated with trauma or follow attempts at central venous catheter insertion. The diagnosis is made clinically or by ultrasound. Decompress rapidly by thoracostomy or needle thoracocentesis, and then insert a chest drain. In the context of cardiac arrest from major trauma, consider bilateral thoracostomies for decompression of a suspected tension pneumothorax (Section 4). 224 Cardiac tamponade is difficult to diagnose because the typical signs of distended neck veins and hypotension are usually obscured by the arrest itself. Cardiac arrest after penetrating chest trauma is highly suggestive of tamponade and is an indication for resuscitative thoracotomy (Section 4). 224 The use of ultrasound will make the diagnosis of cardiac tamponade much more reliable.
In the absence of a specific history, the accidental or deliberate ingestion of therapeutic or toxic substances may be revealed only by laboratory investigations (Section 4). 224 Where available, the appropriate antidotes should be used, but most often treatment is supportive and standard ALS protocols should be followed.
Use of ultrasound imaging during advanced life support
Several studies have examined the use of ultrasound during cardiac arrest to detect potentially reversible causes. [372] [373] [374] Although no studies have shown that use of this imaging modality improves outcome, there is no doubt that echocardiography has the potential to detect reversible causes of cardiac arrest. Specific protocols for ultrasound evaluation during CPR may help to identify potentially reversible causes (e.g. cardiac tamponade, pulmonary embolism, hypovolaemia, pneumothorax) and identify pseudo-PEA. 373, [375] [376] [377] [378] [379] [380] [381] [382] When available for use by trained clinicians, ultrasound may be of use in assisting with diagnosis and treatment of potentially reversible causes of cardiac arrest. The integration of ultrasound into advanced life support requires considerable training if interruptions to chest compressions are to be minimised. A sub-xiphoid probe position has been recommended. 375, 381, 383 Placement of the probe just before chest compressions are paused for a planned rhythm assessment enables a well-trained operator to obtain views within 10 s.
Absence of cardiac motion on sonography during resuscitation of patients in cardiac arrest is highly predictive of death although sensitivity and specificity has not been reported. [384] [385] [386] [387] Monitoring during advanced life support
There are a number of methods and emerging technologies to monitor the patient during CPR and potentially help guide ALS interventions. These include:
• Clinical signs such as breathing efforts, movements and eye opening can occur during CPR. These can indicate ROSC and require verification by a rhythm and pulse check, but can also occur because CPR can generate a sufficient circulation to restore signs of life including consciousness. 388 • The use of CPR feedback or prompt devices during CPR is addressed in Section 2 -basic life support. 223 The use of CPR feedback or prompt devices during CPR should only be considered as part of a broader system of care that should include comprehensive CPR quality improvement initiatives 389, 390 rather than an isolated intervention.
• Pulse checks when there is an ECG rhythm compatible with an output can be used to identify ROSC, but may not detect pulses in those with low cardiac output states and a low blood pressure. 391 The value of attempting to feel arterial pulses during chest compressions to assess the effectiveness of chest compressions is unclear. A pulse that is felt in the femoral triangle may indicate venous rather than arterial blood flow. There are no valves in the inferior vena cava and retrograde blood flow into the venous system can produce femoral vein pulsations. 392 Carotid pulsation during CPR does not necessarily indicate adequate myocardial or cerebral perfusion.
• ECG monitoring of heart rhythm. Monitoring heart rhythm through pads, paddles or ECG electrodes is a standard part of ALS. Motion artefacts prevent reliable heart rhythm assessment during chest compressions forcing rescuers to stop chest compressions to assess the rhythm, and preventing early recognition of recurrent VF/pVT. Some modern defibrillators have filters that remove artefact from compressions but there are no human studies showing improvements in patient outcomes from their use. We suggest against the routine use of artefact-filtering algorithms for analysis of ECG rhythm during CPR unless as part of a research programme. 393 • End-tidal carbon dioxide with waveform capnography. The use of waveform capnography during CPR has a greater emphasis in Guidelines 2015 and is addressed in more detail below.
• Blood sampling and analysis during CPR can be used to identify potentially reversible causes of cardiac arrest. Avoid finger prick samples in critical illness because they may not be reliable; instead, use samples from veins or arteries.
• Blood gas values are difficult to interpret during CPR. During cardiac arrest, arterial gas values may be misleading and bear little relationship to the tissue acid-base state. 394 Analysis of central venous blood may provide a better estimation of tissue pH. 395 In practice this would mean measuring an arterial diastolic pressure. Although haemodynamic-directed CPR showed some benefit in experimental studies [396] [397] [398] [399] there is currently no evidence of improvement in survival with this approach in humans. 4 • Ultrasound assessment is addressed above to identify and treat reversible causes of cardiac arrest, and identify low cardiac output states ('pseudo-PEA'). Its use has been discussed above.
• Cerebral oximetry using near-infrared spectroscopy measures regional cerebral oxygen saturation (rSO2) non-invasively. [400] [401] [402] This remains an emerging technology that is feasible during CPR. Its role in guiding CPR interventions including prognostication during and after CPR is yet to be established. 403 Waveform capnography during advanced life support End-tidal carbon dioxide is the partial pressure of carbon dioxide (CO 2 ) at the end of an exhaled breath. It reflects cardiac output and pulmonary blood flow, as CO 2 is transported by the venous system to the right side of the heart and then pumped to the lungs by the right ventricle, as well as the ventilation minute volume. During CPR, end-tidal CO 2 values are low, reflecting the low cardiac output generated by chest compression. Waveform capnography enables continuous real time end-tidal CO 2 to be monitored during CPR. It works most reliably in patients who have a tracheal tube, but can also be used with a supraglottic airway device or bag mask. There is currently no evidence that use of waveform capnography during CPR results in improved patient outcomes, although the prevention of unrecognised oesophageal intubation is clearly beneficial. The role of waveform capnography during CPR includes:
• Ensuring tracheal tube placement in the trachea (see below for further details).
• Monitoring ventilation rate during CPR and avoiding hyperventilation.
• Monitoring the quality of chest compressions during CPR. Endtidal CO 2 values are associated with compression depth and ventilation rate and a greater depth of chest compression will increase the value. 404 Whether this can be used to guide care and improve outcome requires further study. 295 ( Fig. 3.3 295, 406, 407 Failure to achieve an end-tidal CO 2 value >1.33 kPa (10 mmHg) after 20 min of CPR is associated with a poor outcome in observational studies. 4 In addition it has been used as a criterion for withholding extracorporeal life support in patients with refractory cardiac arrest. 408 The interindividual differences and influence of cause of cardiac arrest, the problem with self-fulfilling prophecy in studies, our lack of In this example the patient's trachea is intubated at zero minutes. The patient is then ventilated at 10 breaths min −1 and given chest compressions (indicated by CPR) at about two per second. A minute after tracheal intubation, there is pause in chest compressions and ventilation followed by a defibrillation attempt, and chest compressions and ventilation then continue. Higher-quality chest compressions lead to an increased end-tidal carbon dioxide value. There is a further defibrillation attempt after two minutes of chest compressions. There are then further chest compressions and ventilation. There is a significant increase in the end-tidal carbon dioxide value during chest compressions and the patient starts moving and eye opening. Chest compressions are stopped briefly and there is a pulse indicating ROSC. Ventilation continues at 10 breaths min −1 . CPR -cardiopulmonary resuscitation; ROSC -return of spontaneous circulation; End tidal CO2 -end-tidal carbon dioxide; HR -heart rate; RR -respiratory rate.
confidence in the accuracy of measurement during CPR, and the need for an advanced airway to measure end-tidal CO 2 reliably limits our confidence in its use for prognostication. Thus, we recommend that a specific end-tidal CO 2 value at any time during CPR should not be used alone to stop CPR efforts. End-tidal CO 2 values should be considered only as part of a multi-modal approach to decision-making for prognostication during CPR.
Extracorporeal cardiopulmonary resuscitation (eCPR)
Extracorporeal CPR (eCPR) should be considered as a rescue therapy for those patients in whom initial ALS measures are unsuccessful and, or to facilitate specific interventions (e.g. coronary angiography and percutaneous coronary intervention (PCI) or pulmonary thrombectomy for massive pulmonary embolism). 409, 410 There is an urgent need for randomised studies of eCPR and large eCPR registries to identify the circumstances in which it works best, establish guidelines for its use and identify the benefits, costs and risks of eCPR. 411, 412 Extracorporeal techniques require vascular access and a circuit with a pump and oxygenator and can provide a circulation of oxygenated blood to restore tissue perfusion. This has the potential to buy time for restoration of an adequate spontaneous circulation, and treatment of reversible underlying conditions. This is commonly called extracorporeal life support (ECLS), and more specifically extracorporeal CPR (eCPR) when used during cardiac arrest. These techniques are becoming more commonplace and have been used for both in-hospital and out-of-hospital despite limited observational data in select patient groups. Observational studies suggest eCPR for cardiac arrest is associated with improved survival when there is a reversible cause for cardiac arrest (e.g. myocardial infarction, pulmonary embolism, severe hypothermia, poisoning), there is little comorbidity, the cardiac arrest is witnessed, the individual receives immediate high-quality CPR, and eCPR is implemented early (e.g. within 1 h of collapse) including when instituted by emergency physicians and intensivists. [413] [414] [415] [416] [417] [418] [419] The implementation of eCPR requires considerable resource and training. When compared with manual or mechanical CPR, eCPR has been associated with improve survival after IHCA in selected patients. 413, 415 After OHCA outcomes with both standard and eCPR are less favourable. 420 The duration of standard CPR before eCPR is established and patient selection are important factors for success. 409, 413, 417, 419, [421] [422] [423] 
3e -Defibrillation
This section predominantly addresses the use of manual defibrillators. Guidelines concerning the use of an automated external defibrillator (AED) are addressed in Section 2 -Basic Life Support. 223 The defibrillation strategy for the 2015 European Resuscitation Council (ERC) guidelines has changed little from the former guidelines:
• The importance of early, uninterrupted chest compressions remains emphasised throughout these guidelines, together with minimising the duration of pre-shock and post-shock pauses.
• Continue chest compressions during defibrillator charging, deliver defibrillation with an interruption in chest compressions of no more than 5 s and immediately resume chest compressions following defibrillation.
• Self-adhesive defibrillation pads have a number of advantages over manual paddles and should always be used in preference when they are available.
• CPR should be continued while a defibrillator or automated external defibrillator (AED) is retrieved and applied but defibrillation should not be delayed longer than needed to establish the need for defibrillation and charging.
• The use of up to three-stacked shocks may be considered if initial VF/pVT occurs during a witnessed, monitored arrest with a defibrillator immediately available e.g. cardiac catheterisation.
• Although it is recognised that some geographic areas continue to use the older monophasic waveforms, they are not considered in this chapter. When possible, biphasic waveforms should be used in preference to the older monophasic waveform for the treatment of both atrial and ventricular arrhythmias. Defibrillation recommendations in these guidelines apply only to biphasic waveforms. For those using monophasic defibrillators, please refer to Guidelines 2010. 2 • Defibrillation shock energy levels are unchanged from the 2010 guidelines. 2 For biphasic waveforms (rectilinear biphasic or biphasic truncated exponential), deliver the first shock with an energy of at least 150 J. For pulsed biphasic waveforms, begin at 120-150 J. The shock energy for a particular defibrillator should be based on the manufacturer's guidance. It is important that those using manual defibrillators are aware of the appropriate energy settings for the type of device used. Manufacturers should consider labelling their manual defibrillators with energy level instructions, but in the absence of this and if appropriate energy levels are unknown, for adults use the highest available shock energy for all shocks. With manual defibrillators it is appropriate to consider escalating the shock energy if feasible, after a failed shock and for patients where refibrillation occurs. 326, 327 There are no high-quality clinical studies to indicate the optimal strategies within any given waveform and between different waveforms. 4 Knowledge gaps include the minimal acceptable firstshock energy level; the characteristics of the optimal biphasic waveform; the optimal energy levels for specific waveforms; and the best shock strategy (fixed versus escalating). It is becoming increasingly clear that selected energy is a poor comparator with which to assess different waveforms as impedance-compensation and subtleties in waveform shape result in significantly different transmyocardial current between devices for any given selected energy. The optimal energy levels may ultimately vary between different manufacturers and associated waveforms. Manufacturers are encouraged to undertake high-quality clinical trials to support their defibrillation strategy recommendations.
Strategies for minimising the pre-shock pause
The delay between stopping chest compressions and delivery of the shock (the pre-shock pause) must be kept to an absolute minimum; even 5-10 s delay will reduce the chances of the shock being successful. [328] [329] [330] [331] 424, 425 The pre-shock pause can be reduced to less than 5 s by continuing compressions during charging of the defibrillator and by having an efficient team coordinated by a leader who communicates effectively. 297, 426 The safety check to avoid rescuer contact with the patient at the moment of defibrillation should be undertaken rapidly but efficiently. The post shock pause is minimised by resuming chest compressions immediately after shock delivery (see below). The entire process of manual defibrillation should be achievable with less than a 5 s interruption to chest compressions.
Hands-on defibrillation
By allowing continuous chest compressions during the delivery of the defibrillation shock, hands-on defibrillation can minimise peri-shock pause and allow continuation of chest compressions during defibrillation. The benefits of this approach are not proven and further studies are required to assess the safety and efficacy of this technique. A recent study did not observe a benefit when shocks were delivered without pausing manual or mechanical chest compressions. 427 Standard clinical examination gloves (or bare hands) do not provide a safe level of electrical insulation for handson defibrillation. 428 
Safe use of oxygen during defibrillation
In an oxygen-enriched atmosphere, sparking from poorly applied defibrillator paddles can cause a fire and significant burns to a patient. [429] [430] [431] [432] [433] [434] The absence of case reports of fires caused by sparking where defibrillation was delivered using self-adhesive defibrillation pads suggests that the latter minimise the risk of electrical arcing and should always be used when possible.
• The risk of fire during attempted defibrillation can be minimised by taking the following precautions: • Take off any oxygen mask or nasal cannulae and place them at least 1 m away from the patient's chest.
• Leave the ventilation bag connected to the tracheal tube or supraglottic airway, ensuring that there is no residual PEEP remaining in the circuit.
• If the patient is connected to a ventilator, for example in the operating room or critical care unit, leave the ventilator tubing (breathing circuit) connected to the tracheal tube unless chest compressions prevent the ventilator from delivering adequate tidal volumes. In this case, the ventilator is usually substituted by a ventilation bag, which can itself be left connected. If not in use, switch off the ventilator to prevent venting large volumes of oxygen into the room or alternatively connect it to a test lung. During normal use, when connected to a tracheal tube, oxygen from a ventilator in the critical care unit will be vented from the main ventilator housing well away from the defibrillation zone. Patients in the critical care unit may be dependent on positive end expiratory pressure (PEEP) to maintain adequate oxygenation; during cardioversion, when the spontaneous circulation potentially enables blood to remain well oxygenated, it is particularly appropriate to leave the critically ill patient connected to the ventilator during shock delivery.
The technique for electrode contact with the chest
The techniques described below aim to place external defibrillation electrodes (self-adhesive pads) in an optimal position using techniques that minimise transthoracic impedance.
Electrode position
No human studies have evaluated the electrode position as a determinant of ROSC or survival from VF/pVT. Transmyocardial current during defibrillation is likely to be maximal when the electrodes are placed so that the area of the heart that is fibrillating lies directly between them (i.e. ventricles in VF/pVT, atria in AF). Therefore, the optimal electrode position may not be the same for ventricular and atrial arrhythmias.
More patients are presenting with implantable medical devices (e.g. permanent pacemaker, implantable cardioverter defibrillator (ICD)). Medic alert bracelets are recommended for these patients. These devices may be damaged during defibrillation if current is discharged through electrodes placed directly over the device. 435, 436 Place the electrode away from the device (at least 8 cm) or use an alternative electrode position (anterior-lateral, anterior-posterior) as described below. 435 Placement for ventricular arrhythmias and cardiac arrest. Place electrodes (either pads or paddles) in the conventional sternal-apical position. The right (sternal) electrode is placed to the right of the sternum, below the clavicle. The apical paddle is placed in the left mid-axillary line, approximately level with the V6 ECG electrode. This position should be clear of any breast tissue. 437 It is important that this electrode is placed sufficiently laterally. Other acceptable pad positions include
• Placement of each electrode on the lateral chest walls, one on the right and the other on the left side (bi-axillary).
• One electrode in the standard apical position and the other on the right upper back.
• One electrode anteriorly, over the left precordium, and the other electrode posteriorly to the heart just inferior to the left scapula.
It does not matter which electrode (apex/sternum) is placed in either position. The long axis of the apical paddle should be orientated in a cranio-caudal direction to minimise transthoracic impedance. 438 Placement for atrial arrhythmias. Atrial fibrillation is maintained by functional re-entry circuits anchored in the left atrium. As the left atrium is located posteriorly in the thorax, electrode positions that result in a more posterior current pathway may theoretically be more effective for atrial arrhythmias. Although some studies have shown that antero-posterior electrode placement is more effective than the traditional antero-apical position in elective cardioversion of atrial fibrillation, 439, 440 the majority have failed to demonstrate any clear advantage of any specific electrode position. [441] [442] [443] [444] Efficacy of cardioversion may be less dependent on electrode position when using biphasic impedance-compensated waveforms. [443] [444] [445] The following electrode positions all appear safe and effective for cardioversion of atrial arrhythmias:
• Traditional antero-apical position.
• Antero-posterior position (one electrode anteriorly, over the left precordium, and the other electrode posteriorly to the heart just inferior to the left scapula).
Respiratory phase
Transthoracic impedance varies during respiration, being minimal at end-expiration. If possible, defibrillation should be attempted at this phase of the respiratory cycle. Positive end expiratory pressure (PEEP) increases transthoracic impedance and should be minimised during defibrillation. Auto-PEEP (gas trapping) may be particularly high in asthmatics and may necessitate higher than usual energy levels for defibrillation. 446 
Fibrillation waveform analysis
It is possible to predict, with varying reliability, the success of defibrillation from the fibrillation waveform. 342, 343, If optimal defibrillation waveforms and the optimal timing of shock delivery can be determined in prospective studies, it should be possible to prevent the delivery of unsuccessful high energy shocks and minimise myocardial injury. This technology is under active development and investigation but current sensitivity and specificity is insufficient to enable introduction of VF waveform analysis into clinical practice.
CPR versus defibrillation as the initial treatment
This aspect has been dealt with in detail above in 4b -prehospital resuscitation. Rescuers should provide high-quality CPR while a defibrillator is retrieved, applied and charged. Do not delay defibrillation longer than needed to establish the need for defibrillation and charging. The routine delivery of a pre-specified period of CPR (e.g. 2 or 3 min) before rhythm analysis and a shock is delivered is not recommended.
One shock versus three stacked shock sequence In 2010, it was recommended that when defibrillation was required, a single shock should be provided with immediate resumption of chest compressions after the shock. 468, 469 This recommendation was made for two reasons. Firstly in an attempt to minimise peri-shock interruptions to chest compressions and secondly because it was felt that with the greater efficacy of biphasic shocks, if a biphasic shock failed to defibrillate, a further period of chest compressions could be beneficial.
Studies since 2010 have not shown that any specific shock strategy is of benefit for any survival end-point. 470, 471 There is no conclusive evidence that a single shock strategy is of benefit for ROSC or recurrence of VF compared with three stacked shocks, but in view of the evidence suggesting that outcome is improved by minimising interruptions to chest compressions, we continue to recommend single shocks for most situations.
When defibrillation is warranted, give a single shock and resume chest compressions immediately following the shock. Do not delay CPR for rhythm reanalysis or a pulse check immediately after a shock. Continue CPR (30 compressions: 2 ventilations) for 2 min until rhythm reanalysis is undertaken and another shock given (if indicated). Even if the defibrillation attempt is successful, it takes time until the post shock circulation is established 332 and it is very rare for a pulse to be palpable immediately after defibrillation. 333 Patients can remain pulseless for over 2 min and the duration of asystole before ROSC can be longer than 2 min in as many as 25% of successful shocks. 334 If a patient has a monitored and witnessed cardiac arrest in the catheter laboratory, coronary care unit, a critical care area or whilst monitored after cardiac surgery, and a manual defibrillator is rapidly available:
• Rapidly check for a rhythm change and if appropriate ROSC after each defibrillation attempt.
Waveforms
Biphasic waveforms, are now well established as a safe and effective waveform for defibrillation. Biphasic defibrillators compensate for the wide variations in transthoracic impedance by electronically adjusting the waveform magnitude and duration to ensure optimal current delivery to the myocardium, irrespective of the patient's size (impedance compensation). There are two main types of biphasic waveform: the biphasic truncated exponential (BTE) and rectilinear biphasic (RLB). A pulsed biphasic waveform is also in clinical use, in which the current rapidly oscillates between baseline and a positive value before inverting in a negative pattern. It may have a similar efficacy as other biphasic waveforms, but the single clinical study of this waveform was not performed with an impedance compensating waveform, which is used in the commercially available product. 472, 473 We recommend that a biphasic waveform is used for cardioversion of both atrial and ventricular arrhythmias in preference to a monophasic waveform. We place a high value on the reported higher first shock success rate for termination of fibrillation with a biphasic waveform, the potential for less post shock myocardial dysfunction and the existing 2010 Guidelines. 1, 2, 468, 469 We acknowledge that many emergency medical services (EMS) systems and hospitals continue to use older monophasic devices. For those using monophasic defibrillators, please refer to Guidelines 2010. 2 
Energy levels
Defibrillation requires the delivery of sufficient electrical energy to defibrillate a critical mass of myocardium, abolish the wavefronts of VF and enable restoration of spontaneous synchronised electrical activity in the form of an organised rhythm. The optimal energy for defibrillation is that which achieves defibrillation whilst causing the minimum of myocardial damage. 474 Selection of an appropriate energy level also reduces the number of repetitive shocks, which in turn limits myocardial damage. 475 Optimal energy levels for defibrillation are unknown. The recommendations for energy levels are based on a consensus following careful review of the current literature. Although delivered energy levels are selected for defibrillation, it is the transmyocardial current flow that achieves defibrillation. Current correlates well with successful defibrillation and cardioversion. 476 Defibrillation shock energy levels are unchanged from the 2010 guidelines. 2 
First shock
Relatively few studies have been published in the past five years on which to refine the 2010 guidelines. There is no evidence that one biphasic waveform or device is more effective than another. First shock efficacy of the BTE waveform using 150-200 J has been reported as 86-98%. [477] [478] [479] [480] [481] First shock efficacy of the RLB waveform using 120 J is up to 85%. 327 First shock efficacy of a new pulsed biphasic waveform at 130 J showed a first shock success rate of 90%. 472 Two studies have suggested equivalence with lower and higher starting energy biphasic defibrillation. 482, 483 Although human studies have not shown harm (raised biomarkers, ECG changes, ejection fraction) from any biphasic waveform up to 360 J, 482, 484 several animal studies have suggested the potential for harm with higher energy levels. [485] [486] [487] [488] The initial biphasic shock should be no lower than 120 J for RLB waveforms and at least 150 J for BTE waveforms. Ideally, the initial biphasic shock energy should be at least 150 J for all waveforms. Manufacturers should display the effective waveform dose range on the face of the biphasic defibrillator. If the rescuer is unaware of the recommended energy settings of the defibrillator, use the highest setting for all shocks.
Second and subsequent shocks
The 2010 guidelines recommended either a fixed or escalating energy strategy for defibrillation. Several studies demonstrated that although an escalating strategy reduces the number of shocks required to restore an organised rhythm compared with fixeddose biphasic defibrillation, and may be needed for successful defibrillation, 326, 489 rates of ROSC or survival to hospital discharge are not significantly different between strategies. 482, 483 Conversely, a fixed-dose biphasic protocol demonstrated high cardioversion rates (>90%) with a three-shock fixed dose protocol but the small number of cases did not exclude a significant lower ROSC rate for recurrent VF. 490 Several in-hospital studies using an escalating shock energy strategy have demonstrated improvement in cardioversion rates (compared with fixed dose protocols) in non-arrest rhythms with the same level of energy selected for both biphasic and monophasic waveforms. [491] [492] [493] [494] [495] [496] Animal studies, case reports and small case series have documented the use of two defibrillators to deliver a pair of shocks at the same time ('dual sequential defibrillation') to patients in refractory shockable states. [497] [498] [499] [500] [501] Given the very limited evidence, the routine use of dual sequential defibrillation' cannot be recommended.
There remains no evidence to support either a fixed or escalating energy protocol, although an escalating protocol may be associated with a lower incidence of refibrillation (see below). Both strategies are acceptable; however, if the first shock is not successful and the defibrillator is capable of delivering shocks of higher energy it is reasonable to increase the energy for subsequent shocks.
Recurrent ventricular fibrillation (refibrillation).
Refibrillation is common and occurs in the majority of patients following initial first-shock termination of VF. Refibrillation was not specifically addressed in 2010 guidelines. Distinct from refractory VF, defined as 'fibrillation that persists after one or more shocks', recurrence of fibrillation is usually defined as 'recurrence of VF during a documented cardiac arrest episode, occurring after initial termination of VF while the patient remains under the care of the same providers (usually out-of-hospital).' Two studies showed termination rates of subsequent refibrillation were unchanged when using fixed 120 J or 150 J shock protocols respectively, 490,502 but a larger study showed termination rates of refibrillation declined when using repeated 200 J shocks, unless an increased energy level (360 J) was selected. 326 In a retrospective analysis, termination rate of VF into a pulse generating rhythm was higher if the VF appeared after a pulse generating rhythm, than after PEA or asystole. 503 In view of the larger study suggesting benefit from higher subsequent energy levels for refibrillation, 326 we recommend that if a shockable rhythm recurs after successful defibrillation with ROSC, and the defibrillator is capable of delivering shocks of higher energy it is reasonable to increase the energy for subsequent shocks.
Other related defibrillation topics Cardioversion
If electrical cardioversion is used to convert atrial or ventricular tachyarrhythmias, the shock must be synchronised to occur with the R wave of the electrocardiogram rather than with the T wave: VF can be induced if a shock is delivered during the relative refractory portion of the cardiac cycle. 504 Synchronisation can be difficult in VT because of the wide-complex and variable forms of ventricular arrhythmia. Inspect the synchronisation marker carefully for consistent recognition of the R wave. If needed, choose another lead and/or adjust the amplitude. If synchronisation fails, give unsynchronised shocks to the unstable patient in VT to avoid prolonged delay in restoring sinus rhythm. Ventricular fibrillation or pulseless VT requires unsynchronised shocks. Conscious patients require anaesthesia or sedation, and analgesia before attempting synchronised cardioversion.
Atrial fibrillation. Optimal electrode position has been discussed previously, but anterolateral and anteroposterior are both acceptable positions. 443 Biphasic waveforms are more effective than monophasic waveforms for cardioversion of AF 493, 494, 505, 506 ; and cause less severe skin burns. 507 More data are needed before specific recommendations can be made for optimal biphasic energy levels and different biphasic waveforms. Biphasic rectilinear and biphasic truncated exponential waveform show similar high efficacy in the elective cardioversion of atrial fibrillation. 508 Commencing at high energy levels has not shown to result in more successful cardioversion rates compared to lower energy levels. 494, [509] [510] [511] [512] [513] [514] An initial synchronised shock of 120-150 J, escalating if necessary is a reasonable strategy based on current data.
Atrial flutter and paroxysmal supraventricular tachycardia. Atrial flutter and paroxysmal SVT generally require less energy than atrial fibrillation for cardioversion. 513 Give an initial shock of 70-120 J biphasic. Give subsequent shocks using stepwise increases in energy. 476 Ventricular tachycardia. The energy required for cardioversion of VT depends on the morphological characteristics and rate of the arrhythmia. 515 Ventricular tachycardia with a pulse responds well using biphasic energy levels of 120-150 J for the initial shock. Consider stepwise increases if the first shock fails to achieve sinus rhythm. 515 
Pacing
Consider pacing in patients with symptomatic bradycardia refractory to anti-cholinergic drugs or other second line therapy. Immediate pacing is indicated especially when the block is at or below the His-Purkinje level. If transthoracic pacing is ineffective, consider transvenous pacing. Whenever a diagnosis of asystole is made, check the ECG carefully for the presence of P waves because this will likely respond to cardiac pacing. The use of epicardial wires to pace the myocardium following cardiac surgery is effective and discussed elsewhere. Do not attempt pacing for asystole unless P waves are present; it does not increase short or long-term survival in-or out-of-hospital. [516] [517] [518] [519] [520] [521] [522] [523] [524] For haemodynamically unstable, conscious patients with bradyarrhythmias, percussion pacing as a bridge to electrical pacing may be attempted, although its effectiveness has not been established. 525, 526 Implantable cardioverter defibrillators Implantable cardioverter defibrillators (ICDs) are becoming increasingly common as the devices are implanted more frequently as the population ages. They are implanted because a patient is considered to be at risk from, or has had, a life-threatening shockable arrhythmia and are usually embedded under the pectoral muscle below the left clavicle (in a similar position to pacemakers, from which they cannot be immediately distinguished). More recently, extravascular devices can be implanted subcutaneously in the left chest wall, with a lead running to the left of the sternum.
On sensing a shockable rhythm, an ICD will discharge approximately 40 J (approximately 80 J for subcutaneous devices) through an internal pacing wire embedded in the right ventricle. On detecting VF/pVT, ICD devices will discharge no more than eight times, but may reset if they detect a new period of VF/pVT. Patients with fractured ICD leads may suffer repeated internal defibrillation as the electrical noise is mistaken for a shockable rhythm; in these circumstances, the patient is likely to be conscious, with the ECG showing a relatively normal rate. A magnet placed over the ICD will disable the defibrillation function in these circumstances.
Discharge of an ICD may cause pectoral muscle contraction in the patient, and shocks to the rescuer have been documented. 527 In view of the low energy levels discharged by conventional ICDs, it is unlikely that any harm will come to the rescuer, but minimising contact with the patient whilst the device is discharging is prudent. Surface current from subcutaneous ICDs is currently under investigation. Cardioverter and pacing function should always be re-evaluated following external defibrillation, both to check the device itself and to check pacing/defibrillation thresholds of the device leads.
Pacemaker spikes generated by devices programmed to unipolar pacing may confuse AED software and emergency personnel, and may prevent the detection of VF. 528 The diagnostic algorithms of modern AEDs can be insensitive to such spikes.
3f -Airway management and ventilation
Introduction
The optimal strategy for managing the airway has yet to be determined. Several observational studies have challenged the premise that advanced airway interventions (tracheal intubation or supraglottic airways) improve outcomes. 529 Options for airway management and ventilation during CPR include: no airway and no ventilation (compression-only CPR), compression-only CPR with the airway held open (with or without supplementary oxygen), mouth-to-mouth breaths, mouth-to-mask, bag-mask ventilation with simple airway adjuncts, supraglottic airways (SGAs), and tracheal intubation (inserted with the aid of direct laryngoscopy or videolaryngoscopy, or via a SGA). In practice a combination of airway techniques will be used stepwise during a resuscitation attempt. 530 The best airway, or combination of airway techniques will vary according to patient factors, the phase of the resuscitation attempt (during CPR, after ROSC), and the skills of rescuers. 311 A stepwise approach to airway and ventilation management using a combination of techniques is therefore suggested. Compression-only CPR and use of ventilation during basic life support is addressed in Section 2 -Basic Life Support. 223 Patients requiring resuscitation often have an obstructed airway, usually secondary to loss of consciousness, but occasionally it may be the primary cause of cardiorespiratory arrest. Prompt assessment, with control of the airway and ventilation of the lungs, is essential. This will help to prevent secondary hypoxic damage to the brain and other vital organs. Without adequate oxygenation it may be impossible to achieve ROSC. These principles may not apply to the witnessed primary cardiac arrest in the vicinity of a defibrillator; in this case, the priority is immediate defibrillation.
Airway obstruction
Causes of airway obstruction
Obstruction of the airway may be partial or complete. It may occur at any level, from the nose and mouth down to the trachea. In the unconscious patient, the commonest site of airway obstruction is at the soft palate and epiglottis. 531, 532 Obstruction may also be caused by vomit or blood (regurgitation of gastric contents or trauma), or by foreign bodies. Laryngeal obstruction may be caused by oedema from burns, inflammation or anaphylaxis. Upper airway stimulation may cause laryngeal spasm. Obstruction of the airway below the larynx is less common, but may arise from excessive bronchial secretions, mucosal oedema, bronchospasm, pulmonary oedema or aspiration of gastric contents.
Recognition of airway obstruction
Airway obstruction can be subtle and is often missed by healthcare professionals, let alone by laypeople. The 'look, listen and feel' approach is a simple, systematic method of detecting airway obstruction.
• Look for chest and abdominal movements.
• Listen and feel for airflow at the mouth and nose.
In partial airway obstruction, air entry is diminished and usually noisy. Inspiratory stridor is caused by obstruction at the laryngeal level or above. Expiratory wheeze implies obstruction of the lower airways, which tend to collapse and obstruct during expiration. In a patient who is making respiratory efforts, complete airway obstruction causes paradoxical chest and abdominal movement, often described as 'see-saw' breathing. During airway obstruction, other accessory muscles of respiration are used, with the neck and the shoulder muscles contracting to assist movement of the thoracic cage.
Basic airway management
There are three manoeuvres that may improve the patency of an airway obstructed by the tongue or other upper airway structures: head tilt, chin lift, and jaw thrust.
Head tilt and chin lift
The rescuer's hand is placed on the patient's forehead and the head gently tilted back; the fingertips of the other hand are placed under the point of the patient's chin, which is lifted gently to stretch the anterior neck structures. [533] [534] [535] [536] [537] [538] 
Jaw thrust
Jaw thrust is an alternative manoeuvre for bringing the mandible forward and relieving obstruction by the soft palate and epiglottis. The rescuer's index and other fingers are placed behind the angle of the mandible, and pressure is applied upwards and forwards. Using the thumbs, the mouth is opened slightly by downward displacement of the chin.
Airway management in patients with suspected cervical spine injury
When there is a risk of cervical spine injury, establish a clear upper airway by using jaw thrust or chin lift in combination with manual in-line stabilisation (MILS) of the head and neck by an assistant. 539, 540 If life-threatening airway obstruction persists despite effective application of jaw thrust or chin lift, add head tilt in small increments until the airway is open; establishing a patent airway takes priority over concerns about a potential cervical spine injury.
Adjuncts to basic airway techniques
Despite a total lack of published data on the use of nasopharyngeal and oropharyngeal airways during CPR, they are often helpful, and sometimes essential, to maintain an open airway, particularly when resuscitation is prolonged. The position of the head and neck is maintained to keep the airway aligned. Oropharyngeal and nasopharyngeal airways overcome backward displacement of the soft palate and tongue in an unconscious patient, but head tilt and jaw thrust may also be required.
Oropharyngeal airways. Oropharyngeal airways are available in sizes suitable for the newborn to large adults. An estimate of the size required is obtained by selecting an airway with a length corresponding to the vertical distance between the patient's incisors and the angle of the jaw. The most common sizes are 2, 3 and 4 for small, medium and large adults, respectively. Nasopharyngeal airways. In patients who are not deeply unconscious, a nasopharyngeal airway is tolerated better than an oropharyngeal airway. The nasopharyngeal airway may be life saving in patients with clenched jaws, trismus or maxillofacial injuries, when insertion of an oral airway is impossible. The tubes are sized in millimetres according to their internal diameter and the length increases with diameter. Sizes of 6-7 mm are suitable for adults.
Oxygen during CPR
During CPR, give the maximal feasible inspired oxygen concentration. A self-inflating bag can be connected to a facemask, tracheal tube or supraglottic airway (SGA). Without supplementary oxygen, the self-inflating bag ventilates the patient's lungs with ambient air (21% oxygen). The delivered oxygen concentration can be increased to about 85% by using a reservoir system and attaching oxygen at a flow 10 l min −1 . There are no data to indicate the optimal arterial blood oxygen saturation (SaO 2 ) during CPR, and no trials comparing different inspired oxygen concentrations. In one observational study of patients receiving 100% inspired oxygen via a tracheal tube during CPR, a higher measured PaO 2 value during CPR was associated with ROSC and hospital admission. 541 The worse outcomes associated with a low PaO 2 during CPR could however be an indication of illness severity. Animal data and observational clinical data indicate an association between high SaO 2 after ROSC and worse outcome (Section 5 -Post-resuscitation care). 273, [542] [543] [544] After ROSC, as soon as arterial blood oxygen saturation can be monitored reliably (by blood gas analysis and/or pulse oximetry), titrate the inspired oxygen concentration to maintain the arterial blood oxygen saturation in the range of 94-98%. Avoid hypoxaemia, which is also harmful -ensure reliable measurement of arterial oxygen saturation before reducing the inspired oxygen concentration. This is addressed in further detail in Section 5 -post resuscitation care. 273 
Suction
Use a wide-bore rigid sucker (Yankauer) to remove liquid (blood, saliva and gastric contents) from the upper airway. Use the sucker cautiously if the patient has an intact gag reflex; pharyngeal stimulation can provoke vomiting.
Choking
The initial management of foreign body airway obstruction (choking) is addressed in Section 2 -basic life support. 223 In an unconscious patient with suspected foreign body airway obstruction if initial basic measures are unsuccessful use laryngoscopy and forceps to remove the foreign body under direct vision. To do this effectively requires training.
Ventilation
Advanced Life Support providers should give artificial ventilation as soon as possible for any patient in whom spontaneous ventilation is inadequate or absent. Expired air ventilation (rescue breathing) is effective, but the rescuer's expired oxygen concentration is only 16-17%, so it must be replaced as soon as possible by ventilation with oxygen-enriched air. The pocket resuscitation mask is similar to an anaesthetic facemask, and enables mouthto-mask ventilation. It has a unidirectional valve, which directs the patient's expired air away from the rescuer. The mask is transparent so that vomit or blood from the patient can be seen. Some masks have a connector for the addition of oxygen. When using masks without a connector, supplemental oxygen can be given by placing the tubing underneath one side and ensuring an adequate seal. Use a two-hand technique to maximise the seal with the patient's face.
High airway pressures can be generated if the tidal volume or inspiratory flow is excessive, predisposing to gastric inflation and subsequent risk of regurgitation and pulmonary aspiration. The risk of gastric inflation is increased by:
• malalignment of the head and neck, and an obstructed airway;
• an incompetent oesophageal sphincter (present in all patients with cardiac arrest); • a high airway inflation pressure.
Conversely, if inspiratory flow is too low, inspiratory time will be prolonged and the time available to give chest compressions is reduced. Deliver each breath over approximately 1 s, giving a volume that corresponds to normal chest movement; this represents a compromise between giving an adequate volume, minimising the risk of gastric inflation, and allowing adequate time for chest compressions. During CPR with an unprotected airway, give two ventilations after each sequence of 30 chest compressions.
Inadvertent hyperventilation during CPR is common. While this increased intrathoracic pressure 545 and peak airway pressures 546 in small case series in humans, a carefully controlled animal experiment revealed no adverse effects. 547 We suggest a ventilation rate of 10 min −1 during continuous chest compressions with an advanced airway based on very limited evidence. 4 
Self-inflating bag
The self-inflating bag can be connected to a facemask, tracheal tube or supraglottic airway (SGA). Without supplementary oxygen, the self-inflating bag ventilates the patient's lungs with ambient air (21% oxygen). The delivered oxygen concentration can be increased to about 85% by using a reservoir system and attaching oxygen at a flow 10 l min −1 .
Although a bag-mask enables ventilation with high concentrations of oxygen, its use by a single person requires considerable skill. When used with a face mask, it is often difficult to achieve a gas-tight seal between the mask and the patient's face, and to maintain a patent airway with one hand while squeezing the bag with the other. Any significant leak will cause hypoventilation and, if the airway is not patent, gas may be forced into the stomach. 548, 549 This will reduce ventilation further and greatly increase the risk of regurgitation and aspiration. 550 The two-person technique for bagmask ventilation is preferable. Several recent observational studies and a meta-analysis have documented better outcomes with use of bag-mask ventilation compared with more advanced airways (SGA or tracheal tube). 529, [551] [552] [553] [554] However, these observation studies are subject to significant bias caused by confounders such as advanced airways not being required in those patients who achieve ROSC and awaken early.
Once a tracheal tube or a SGA has been inserted, ventilate the lungs at a rate of 10 breaths min −1 and continue chest compressions without pausing during ventilations. The laryngeal seal achieved with a SGA may not be good enough to prevent at least some gas leaking when inspiration coincides with chest compressions. Moderate gas leakage is acceptable, particularly as most of this gas will pass up through the patient's mouth. If excessive gas leakage results in inadequate ventilation of the patient's lungs, chest compressions will have to be interrupted to enable ventilation, using a compression-ventilation ratio of 30:2.
Passive oxygen delivery
In the presence of a patent airway, chest compressions alone may result in some ventilation of the lungs. 555 Oxygen can be delivered passively, either via an adapted tracheal tube (Boussignac tube), 556, 557 or with the combination of an oropharyngeal airway and standard oxygen mask with non-rebreather reservoir. 558 In theory, a SGA can also be used to deliver oxygen passively but this has yet to be studied. One study has shown higher neurologically favourable survival with passive oxygen delivery (oral airway and oxygen mask) compared with bag-mask ventilation after outof-hospital VF cardiac arrest, but this was a retrospective analysis and is subject to numerous confounders. 558 Until further data are available, passive oxygen delivery without ventilation is not recommended for routine use during CPR.
Alternative airway devices
The tracheal tube has generally been considered the optimal method of managing the airway during cardiac arrest. 309 There is evidence that, without adequate training and experience, the incidence of complications, such as unrecognised oesophageal intubation (2.4-17% in several studies involving paramedics) [559] [560] [561] [562] [563] and dislodgement, is unacceptably high. 564 Prolonged attempts at tracheal intubation are harmful; the cessation of chest compressions during this time will compromise coronary and cerebral perfusion. Several alternative airway devices have been used for airway management during CPR. There are published studies on the use during CPR of the Combitube, the classic laryngeal mask airway (cLMA), the laryngeal tube (LT), the i-gel, and the LMA Supreme (LMAS) but none of these studies have been powered adequately to enable survival to be studied as a primary endpoint; instead, most researchers have studied insertion and ventilation success rates. The SGAs are easier to insert than a tracheal tube and, 565 unlike tracheal intubation, can generally be inserted without interrupting chest compressions. 566 There are no data supporting the routine use of any specific approach to airway management during cardiac arrest. The best technique is dependent on the precise circumstances of the cardiac arrest and the competence of the rescuer. It is recognised that during cardiac arrest a stepwise approach to airway management is commonly used, which implies that multiple devices may be used during a single resuscitation attempt.
Laryngeal mask airway (LMA)
The original LMA (classic LMA [cLMA]), which is reusable, has been studied during CPR, but none of these studies has compared it directly with the tracheal tube. Although the cLMA remains in common use in elective anaesthetic practice, it has been superseded by several 2nd generation SGAs that have more favourable characteristics, particularly when used for emergency airway management. 567 Most of these SGAs are single use and achieve higher oropharyngeal seal pressures than the cLMA, and some incorporate gastric drain tubes.
Combitube
The Combitube is a double-lumen tube introduced blindly over the tongue, and provides a route for ventilation whether the tube has passed into the oesophagus. There are many studies of the Combitube in CPR and successful ventilation was achieved in 79-98% of patients. [568] [569] [570] [571] [572] [573] [574] [575] [576] Two RCTs of the Combitube versus tracheal intubation for out-of-hospital cardiac arrest showed no difference in survival. 575, 576 Use of the Combitube is waning and in many parts of the world it is being replaced by other devices such as the LT.
Laryngeal tube
The laryngeal tube (LT) was introduced in 2001; it is known as the King LT airway in the United States. After just 2 h of training, nurses successfully inserted a laryngeal tube and achieved ventilation in 24 of 30 (80%) of OHCAs. 577 In five observational studies, a disposable version of the laryngeal tube (LT-D) was inserted successfully by prehospital personnel in 85-100% of OHCAs (number of cases ranged from 92 to 347). [578] [579] [580] [581] [582] Although some studies are supportive of the use of the LT during cardiac arrest several other studies have reported that insertion problems are common; these include problems with positioning and leakage. 580, 583 i-gel
The cuff of the i-gel is made of thermoplastic elastomer gel and does not require inflation; the stem of the i-gel incorporates a bite block and a narrow oesophageal drain tube. It is very easy to insert, requiring only minimal training and a laryngeal seal pressure of 20-24 cmH 2 O can be achieved. 584, 585 The ease of insertion of the i-gel and its favourable leak pressure make it theoretically very attractive as a resuscitation airway device for those inexperienced in tracheal intubation. In observational studies insertion success rates for the i-gel were 93% (n = 98) when used by paramedics for OHCA 586 and 99% (n = 100) when used by doctors and nurses for IHCA. 587 LMA supreme (LMAS). The LMAS is a disposable version of the Proseal LMA, which is used in anaesthetic practice. In an observational study, paramedics inserted the LMAS successfully and were able to ventilate the lungs of 33 (100%) cases of OHCA. 588 
Tracheal intubation
There is insufficient evidence to support or refute the use of any specific technique to maintain an airway and provide ventilation in adults with cardiopulmonary arrest. Despite this, tracheal intubation is perceived as the optimal method of providing and maintaining a clear and secure airway. 309 It should be used only when trained personnel are available to carry out the procedure with a high level of skill and confidence. A systematic review of randomised controlled trials (RCTs) of tracheal intubation versus alternative airway management in acutely ill and injured patients identified just three trials 589 : two were RCTs of the Combitube versus tracheal intubation for out-of-hospital cardiac arrest, 575, 576 which showed no difference in survival. The third study was a RCT of prehospital tracheal intubation versus management of the airway with a bag-mask in children requiring airway management for cardiac arrest, primary respiratory disorders and severe injuries. 590 There was no overall benefit for tracheal intubation; on the contrary, of the children requiring airway management for a respiratory problem, those randomised to intubation had a lower survival rate that those in the bag-mask group.
The perceived advantages of tracheal intubation over bag-mask ventilation include: enabling ventilation without interrupting chest compressions 591 ; enabling effective ventilation, particularly when lung and/or chest compliance is poor; minimising gastric inflation and therefore the risk of regurgitation; protection against pulmonary aspiration of gastric contents; and the potential to free the rescuer's hands for other tasks. Use of the bag-mask is more likely to cause gastric distension that, theoretically, is more likely to cause regurgitation with risk of aspiration. However, there are no reliable data to indicate that the incidence of aspiration is any more in cardiac arrest patients ventilated with bag-mask versus those that are ventilated via tracheal tube.
The perceived disadvantages of tracheal intubation over bagvalve-mask ventilation include:
• The risk of an unrecognised misplaced tracheal tube -in patients with out-of-hospital cardiac arrest the reliably documented incidence ranges from 0.5% to 17%: emergency physicians-0.5%; 592 paramedics -2.4%, 559 6%, 560,561 9%, 562 17%. 563 • A prolonged period without chest compressions while intubation is attempted -in a study of prehospital intubation by paramedics during 100 cardiac arrests the total duration of the interruptions in CPR associated with tracheal intubation attempts was 110 s (IQR 54-198 s; range 13-446 s) and in 25% the interruptions were more than 3 min. 593 Tracheal intubation attempts accounted for almost 25% of all CPR interruptions.
• A comparatively high failure rate. Intubation success rates correlate with the intubation experience attained by individual paramedics. 594 Rates for failure to intubate are as high as 50% in prehospital systems with a low patient volume and providers who do not perform intubation frequently. 595, 596 • Tracheal intubation is a difficult skill to acquire and maintain. In one study, anaesthesia residents required about 125 intubations in the operating room setting before they were able to achieve and intubation success rate of 95%. 597 Only one study has prospectively compared tracheal intubation with insertion of a SGA in OHCA and this was a feasibility study that is not powered to show differences in survival. 530 A secondary analysis of the North American Resuscitation Outcomes Consortium (ROC) PRIMED study that compared tracheal intubation (n = 8487) with SGAs (LT, Combitube, or LMA; n = 1968) showed that successful tracheal intubation was associated with increased neurologically favourable survival to hospital discharge (adjusted OR 1.40, 95% CI 1.04-1.89) when compared with successful SGA insertion. 598 In a Japanese OHCA study, tracheal intubation (n = 16,054) was compared with the LMA (n = 34,125) and the oesophageal obturator airway (n = 88,069) over a 3-year period. 599 Adjusted ORs for favourable one-month survival were lower for the LMA (0.77, 95% CI 0.64-0.94) and the oesophageal obturator airway (0.81, 95% CI 0.68-0.96) in comparison with tracheal intubation. Even though the data from these two observational studies are risk-adjusted, it is likely that hidden confounders account for the findings.
Healthcare personnel who undertake prehospital intubation should do so only within a structured, monitored programme, which should include comprehensive competency-based training and regular opportunities to refresh skills. Rescuers must weigh the risks and benefits of intubation against the need to provide effective chest compressions. The intubation attempt may require some interruption of chest compressions but, once an advanced airway is in place, ventilation will not require interruption of chest compressions. Personnel skilled in advanced airway management should be able to undertake laryngoscopy without stopping chest compressions; a brief pause in chest compressions will be required only as the tube is passed through the vocal cords. Alternatively, to avoid any interruptions in chest compressions, the intubation attempt may be deferred until ROSC 558, 600 ; this strategy is being studied in a large prehospital randomised trial. 601 The intubation attempt should interrupt chest compressions for less than 5 s; if intubation is not achievable within these constraints, recommence bag-mask ventilation. After intubation, tube placement must be confirmed and the tube secured adequately.
Videolaryngoscopy
Videolaryngoscopes are being used increasingly in anaesthetic and critical care practice. 602, 603 In comparison with direct laryngoscopy, they enable a better view of the larynx and improve the success rate of intubation. Preliminary studies indicate that use of videolaryngoscopes improve laryngeal view and intubation success rates during CPR [604] [605] [606] but further data are required before recommendations can be made for wider use during CPR.
Confirmation of correct placement of the tracheal tube
Unrecognised oesophageal intubation is the most serious complication of attempted tracheal intubation. Routine use of primary and secondary techniques to confirm correct placement of the tracheal tube should reduce this risk.
Clinical assessment. Primary assessment includes observation of chest expansion bilaterally, auscultation over the lung fields bilaterally in the axillae (breath sounds should be equal and adequate) and over the epigastrium (breath sounds should not be heard). Clinical signs of correct tube placement (condensation in the tube, chest rise, breath sounds on auscultation of lungs, and inability to hear gas entering the stomach) are not reliable. The reported sensitivity (proportion of tracheal intubations correctly identified) and specificity (proportion of oesophageal intubations correctly identified) of clinical assessment varies: sensitivity 74-100%; specificity 66-100%. 592, [607] [608] [609] [610] Secondary confirmation of tracheal tube placement by an exhaled carbon dioxide or oesophageal detection device should reduce the risk of unrecognised oesophageal intubation but the performance of the available devices varies considerably. Furthermore, none of the secondary confirmation techniques will differentiate between a tube placed in a main bronchus and one placed correctly in the trachea.
Oesophageal detector device. The oesophageal detector device creates a suction force at the tracheal end of the tracheal tube, either by pulling back the plunger on a large syringe or releasing a compressed flexible bulb. Air is aspirated easily from the lower airways through a tracheal tube placed in the cartilagesupported rigid trachea. When the tube is in the oesophagus, air cannot be aspirated because the oesophagus collapses when aspiration is attempted. The oesophageal detector device may be misleading in patients with morbid obesity, late pregnancy or severe asthma or when there are copious tracheal secretions; in these conditions the trachea may collapse when aspiration is attempted. Detection of correct placement of a tracheal tube during CPR has been documented in five observational studies 561, [611] [612] [613] [614] that included 396 patients, and in one randomised study 615 that included 48 patients. 4 The pooled specificity was 92% (95% CI 84-96%), the pooled sensitivity was 88% (95% CI 84-192%) , and the false positive rate was 0.2% (95% CI, 0-0.6%). One observational study showed no statistically significant difference between the performance of a bulb (sensitivity 71%, specificity 100%) and a syringe (sensitivity 73%, specificity 100%) type oesophageal detection devices in the detection of tracheal placement of a tracheal tube. 615 Thoracic impedance. There are smaller changes in thoracic impedance with oesophageal ventilations than with ventilation of the lungs. [616] [617] [618] Changes in thoracic impedance may be used to detect ventilation 619 and oesophageal intubation 591,620 during cardiac arrest. It is possible that this technology can be used to measure tidal volume during CPR. The role of thoracic impedance as a tool to detect tracheal tube position and adequate ventilation during CPR is undergoing further research but is not yet ready for routine clinical use.
Ultrasound for tracheal tube detection. Three observational studies including 254 patients in cardiac arrest have documented the use of ultrasound to detect tracheal tube placement. [621] [622] [623] The pooled specificity was 90% (95% CI 68-98%), the sensitivity was 100% (95% CI 98-100%), and the FPR was 0.8% (95% CI 0.2-2.6%).
Carbon dioxide detectors. Carbon dioxide (CO 2 ) detector devices measure the concentration of exhaled carbon dioxide from the lungs. The persistence of exhaled CO 2 after six ventilations indicates placement of the tracheal tube in the trachea or a main bronchus. 592 Confirmation of correct placement above the carina will require auscultation of the chest bilaterally in the mid-axillary lines. Broadly, there three types of carbon dioxide detector device:
(1) Disposable colorimetric end-tidal carbon dioxide (ETCO 2 ) detectors use a litmus paper to detect CO 2 , and these devices generally give readings of purple (ETCO 2 < 0.5%), tan (ETCO 2 0.5-2%) and yellow (ETCO 2 > 2%). In most studies, tracheal placement of the tube is considered verified if the tan colour persists after a few ventilations. Seven observational studies 592, 614, [624] [625] [626] [627] [628] including 1119 patients have evaluated the diagnostic accuracy of colorimetric CO 2 devices in cardiac arrest patients. 4 The specificity was 97% (95% CI 84-99%), the sensitivity was 87% (95% CI 85-89%), and the FPR was 0.3% (0-1% 615 including 48 patients showed that the specificity for waveform capnography to detect correct tracheal placement was 100% (95% CI 87-100%). The sensitivity was 100% in one study when waveform capnography was used in the pre-hospital setting immediately after intubation, and oesophageal intubation was less common than the average (1.5%). 592, 607 The sensitivity was between 65% to 68% in the other three studies when the device was used in OHCA patients after intubation in the emergency department (ED). 607, 613, 615 The difference may be related to prolonged resuscitation with compromised or non-existent pulmonary blood flow. Based on the pooled sensitivity/specificity from these studies and assumed oesophageal intubation prevalence of 4.5%, the false positive rate (FPR) of waveform capnography was 0% (95% CI 0-0.6%).
Based on the available data, the accuracy of colorimetric CO 2 detectors, oesophageal detector devices and non-waveform capnometers does not exceed the accuracy of auscultation and direct visualisation for confirming the tracheal position of a tube in victims of cardiac arrest. Waveform capnography is the most sensitive and specific way to confirm and continuously monitor the position of a tracheal tube in victims of cardiac arrest and must supplement clinical assessment (auscultation and visualisation of tube through cords). Waveform capnography will not discriminate between tracheal and bronchial placement of the tube -careful auscultation is essential. Existing portable monitors make capnographic initial confirmation and continuous monitoring of tracheal tube position feasible in almost all settings, including out-of-hospital, emergency department and in-hospital locations where intubation is performed.
The ILCOR ALS Task Force recommends using waveform capnography to confirm and continuously monitor the position of a tracheal tube during CPR in addition to clinical assessment (strong recommendation, low quality evidence). Waveform capnography is given a strong recommendation as it may have other potential uses during CPR (e.g. monitoring ventilation rate, assessing quality of CPR). The ILCOR ALS Task Force recommends that if waveform capnography is not available, a non-waveform carbon dioxide detector, oesophageal detector device or ultrasound in addition to clinical assessment is an alternative (strong recommendation, low quality evidence).
Cricoid pressure
The routine use of cricoid pressure in cardiac arrest is not recommended. If cricoid pressure is used during cardiac arrest, the pressure should be adjusted, relaxed or released if it impedes ventilation or intubation.
In non-arrest patients cricoid pressure may offer some measure of protection to the airway from aspiration but it may also impede ventilation or interfere with intubation. The role of cricoid pressure during cardiac arrest has not been studied. Application of cricoid pressure during bag-mask ventilation reduces gastric inflation. [632] [633] [634] [635] Studies in anaesthetised patients show that cricoid pressure impairs ventilation in many patients, increases peak inspiratory pressures and causes complete obstruction in up to 50% of patients depending on the amount of cricoid pressure (in the range of recommended effective pressure) that is applied. 632, 633, [636] [637] [638] [639] [640] [641] Securing the tracheal tube Accidental dislodgement of a tracheal tube can occur at any time, but may be more likely during resuscitation and during transport. The most effective method for securing the tracheal tube has yet to be determined; use either conventional tapes or ties, or purposemade tracheal tube holders.
Cricothyroidotomy
Occasionally it will be impossible to ventilate an apnoeic patient with a bag-mask, or to pass a tracheal tube or alternative airway device. This may occur in patients with extensive facial trauma or laryngeal obstruction caused by oedema or foreign material. In these circumstances, delivery of oxygen through a needle or surgical cricothyroidotomy may be life-saving. A tracheostomy is contraindicated in an emergency, as it is time consuming, hazardous and requires considerable surgical skill and equipment.
Surgical cricothyroidotomy provides a definitive airway that can be used to ventilate the patient's lungs until semi-elective intubation or tracheostomy is performed. Needle cricothyroidotomy is a much more temporary procedure providing only short-term oxygenation. It requires a wide-bore, non-kinking cannula, a highpressure oxygen source, runs the risk of barotrauma and can be particularly ineffective in patients with chest trauma. It is also prone to failure because of kinking of the cannula, and is unsuitable for patient transfer. In the 4th National Audit Project of the UK Royal College of Anaesthetists and the Difficult Airway Society NAP4, 60% of needle cricothyroidotomies attempted in the intensive care unit (ICU), and elsewhere, failed. 642 In contrast, all surgical cricothyroidotomies achieved access to the trachea. While there may be several underlying causes, these results indicate a need for more training in surgical cricothyroidotomy and this should include regular manikin-based training using locally available equipment. 643 
Summary of airway management for cardiac arrest
The ILCOR ALS Task Force has suggested using either an advanced airway (tracheal intubation or SGA) or a bag-mask for airway management during CPR. 4 This very broad recommendation is made because of the total absence of high quality data to indicate which airway strategy is best.
The type of airway used may depend on the skills and training of the healthcare provider. In comparison with bag-mask ventilation and use of a SGA, tracheal intubation requires considerably more training and practice and may result in unrecognised oesophageal intubation and increased hands-off time. A bag-mask, a SGA and a tracheal tube are frequently used in the same patient as part of a stepwise approach to airway management but this has not been formally assessed. Patients who remain comatose after initial resuscitation from cardiac arrest will ultimately require tracheal intubation regardless of the airway technique used during cardiac arrest. Anyone attempting tracheal intubation must be well trained and equipped with waveform capnography. In the absence of these prerequisites, consider use of bag-mask ventilation and/or an SGA until appropriately experience and equipped personnel are present.
There are very few data relating to airway management during in-hospital cardiac arrest and it is necessary to extrapolate from data derived from out-of-hospital cardiac arrest. On this basis, the principles discussed above apply equally to in-hospital cardiac arrest.
3g -Drugs and fluids for cardiac arrest
This topic is divided into: drugs used during the management of a cardiac arrest; anti-arrhythmic drugs used in the peri-arrest period; other drugs used in the peri-arrest period; and fluids. Every effort has been made to provide accurate information on the drugs in these guidelines, but literature from the relevant pharmaceutical companies will provide the most up-to-date data.
There are three groups of drugs relevant to the management of cardiac arrest that were reviewed during the 2015 Consensus Conference: vasopressors, anti-arrhythmics and other drugs. 4 The systematic reviews found insufficient evidence to comment on critical outcomes such as survival to discharge and survival to discharge with good neurological outcome with either vasopressors or anti-arrhythmic drugs. There was also insufficient evidence to comment on the best time to give drugs to optimise outcome. Thus, although drugs are still included among ALS interventions, they are of secondary importance to high-quality uninterrupted chest compressions and early defibrillation. As an indicator of equipoise regarding the use of drugs during ALS, two large RCTs (adrenaline versus placebo [ISRCTN73485024], and amiodarone versus lidocaine versus placebo 312 [NCT01401647] are currently ongoing.
Vasopressors
Despite the continued widespread use of adrenaline and the use of vasopressin during resuscitation in some countries, there is no placebo-controlled study that shows that the routine use of any vasopressor during human cardiac arrest increases survival to hospital discharge, although improved short-term survival has been documented. 305, 306, 308 The primary goal of CPR is to re-establish blood flow to vital organs until the restoration of spontaneous circulation. Despite the lack of data from cardiac arrest in humans, vasopressors continue to be recommended as a means of increasing cerebral and coronary perfusion pressure during CPR.
Adrenaline (epinephrine) versus no adrenaline
One randomised, placebo-controlled trial on patients with out-of-hospital cardiac arrest from all rhythms showed that administration of standard-dose adrenaline was associated with significantly higher rates of prehospital ROSC (relative risk [RR] 2.80 [95% CI 1.78-4.41], p < 0.00001) and survival to hospital admission (RR 1.95 [95% CI 1.34-2.84], p = 0.0004) when compared to placebo. 308 There was no difference in survival to hospital discharge (RR 2.12 [95% CI 0. .02], p = 0.16) or good neurological outcome, defined as Cerebral Performance Categories (CPC) 1 or 2 (RR 1.73, [95% CI 0.59-5.11], p = 0.32). The trial, however, was stopped early and included only 534 subjects.
Another trial randomised 851 patients with out-of-hospital cardiac arrest to receive advanced life support with or without intravenous drug administration. Results of this trial showed that administration of intravenous drugs was associated with significantly higher rates of prehospital ROSC (40% vs. 25%; p < 0.001) and admission to hospital (43% vs. 29%; p < 0.001). 305 However, the rates of survival to hospital discharge did not differ (10.5 vs.9.2; p = 0.61). The effect on ROSC was most prominent and only significant in the non-shockable group. 305 In a post-hoc analysis comparing patients who were given adrenaline vs. not given adrenaline, the OR of being admitted to hospital was higher with adrenaline, but the likelihood of being discharged from hospital alive and surviving with favourable neurological outcome was reduced [OR for adrenaline vs. no-adrenaline were 2.5 (95% CI 1.9-3.4), 0.5 (95% CI 0.3-0.8) and 0.4 (95% CI 0.2-0.7) respectively]. 644 A series of observational studies on large cohorts of out-ofhospital cardiac arrest patients have compared the outcomes of patients who were administered adrenaline with those of patients who did not receive adrenaline. Adjustments were made using logistic regression and propensity matching. A study conducted in Japan which included a total of 417,188 patients (13,401 of whom were propensity-matched) showed that use of prehospital adrenaline was significantly associated with increased odds of ROSC before hospital arrival (adjusted OR 2. 645 Conversely, another Japanese study conducted on 11,048 propensity-matched, bystander-witnessed arrests showed that prehospital administration of adrenaline was associated with significantly higher rates of overall survival and, for patients with non-shockable rhythms, it was also associated with significantly higher odds of neurologically intact survival (adjusted OR 1.57 [95% CI 1.04-2.37]). 646 However, the absolute increase of neurologically intact survival in this last group of patients was minimal (0.7% vs. 0.4%). Finally, in a recent study in France on 1556 cardiac arrest patients who achieved ROSC and were admitted to hospital, administration of adrenaline was associated with significantly lower odds of neurologically intact survival. 647 There is an increasing concern about the potential detrimental effects of adrenaline. While its alpha-adrenergic, vasoconstrictive effects cause systemic vasoconstriction, which increases macrovascular coronary and cerebral perfusion pressures, its betaadrenergic actions (inotropic, chronotropic) may increase coronary and cerebral blood flow, but with concomitant increases in myocardial oxygen consumption, ectopic ventricular arrhythmias (particularly when the myocardium is acidotic), transient hypoxaemia from pulmonary arteriovenous shunting, impaired microcirculation, 648 and worse post-cardiac arrest myocardial dysfunction. 649, 650 Experimental evidence suggests that epinephrine also impairs cerebral microcirculation. 651 In retrospective secondary analyses, adrenaline use is associated with more rhythm transitions during ALS, both during VF 652 and PEA. 325 Two systematic reviews of adrenaline for OHCA indicate rates of ROSC are increased with adrenaline but good long-term survival (survival to discharge and neurological outcome) is either no better, or worse. 653, 654 The optimal dose of adrenaline is not known, and there are no human data supporting the use of repeated doses. In fact, increasing cumulative dose of epinephrine during resuscitation of patients with asystole and PEA is an independent risk factor for unfavourable functional outcome and in-hospital mortality. 655 Our current recommendation is to continue the use of adrenaline during CPR as for Guidelines 2010. We have considered the benefit in short-term outcomes (ROSC and admission to hospital) and our uncertainty about the benefit or harm on survival to discharge and neurological outcome given the limitations of the observational studies. 4, 653, 654 We have decided not to change current practice until there is high-quality data on longterm outcomes. Dose response and placebo-controlled efficacy trials are needed to evaluate the use of adrenaline in cardiac arrest. We are aware of an ongoing randomised study of adrenaline vs. placebo for OHCA in the UK (PARAMEDIC 2: The Adrenaline Trial, ISRCTN73485024).
Adrenaline (epinephrine) versus vasopressin
The potentially deleterious beta-effects of adrenaline have led to exploration of alternative vasopressors. Vasopressin is a naturally occurring antidiuretic hormone. In very high doses it is a powerful vasoconstrictor that acts by stimulation of smooth muscle V1 receptors. Vasopressin has neither chronotropic nor inotropic effects on the heart. In comparison with adrenaline it has a longer half-life (10-20 min vs. 4 min) and it is potentially more effective during acidosis. 656, 657 Vasopressin has been proposed as an alternative to adrenaline in cardiac arrest, based on the finding that its levels were significantly higher in successfully resuscitated patients than in patients who died. 658 However, a trial comparing up to four doses of either 40 IU vasopressin or 1 mg adrenaline every 5-10 min in patients with out of hospital cardiac arrest did not demonstrate any significant difference in terms of survival to hospital discharge or neurological outcome between the two study arms. 659 This trial had serious methodological issues and included a small number of patients.
A series of randomised controlled trials [660] [661] [662] [663] [664] demonstrated no difference in outcomes (ROSC, survival to discharge, or neurological outcome) with vasopressin versus adrenaline as a first line vasopressor in cardiac arrest. Other studies comparing adrenaline alone or in combination with vasopressin also demonstrated no difference in ROSC, survival to discharge or neurological outcome. [665] [666] [667] There are no alternative vasopressors that provide survival benefit during cardiac arrest resuscitation when compared with adrenaline.
We suggest vasopressin should not be used in cardiac arrest instead of adrenaline. Those healthcare professionals working in systems that already use vasopressin may continue to do so because there is no evidence of harm from using vasopressin when compared to adrenaline. 4 
Steroids
Two studies suggest that a bundled regimen of adrenaline, vasopressin and methylprednisolone improved survival after in-hospital cardiac arrest. In a single-centre randomised, placebocontrolled trial in patients with in-hospital cardiac arrest, a combination of vasopressin 20 IU and adrenaline 1 mg per CPR cycle for the first 5 CPR cycles plus methylprednisolone 40 mg at the first CPR cycle plus hydrocortisone 300 mg in case of post-resuscitation shock was associated with significantly higher rates of ROSC (39/48 [81%] vs. 27 of 52 [52%]; p = 0.003) and survival to hospital discharge (9 [19%] vs. 2 [4%]; p = 0.02) than conventional treatment. 668 These results were confirmed by a subsequent three-centre trial including a total of 300 patients from the same group of investigators. 669 This last trial also showed significantly higher odds of survival with good neurological outcome (CPC = 1-2) (OR 3.28, 95% CI 1.17-9.20; p = 0.02).
The population in these studies had very rapid advanced life support, a high incidence of asystolic cardiac arrest and low baseline survival compared to other in-hospital studies. Thus the findings of these studies are not generalisable to all cardiac arrests and we suggest that steroids are not used routinely for cardiac arrest. 4 Adrenaline Indications. Adrenaline is:
• the first drug used in cardiac arrest of any cause: it is included in the ALS algorithm for use every 3-5 min of CPR (alternate cycles).
• preferred in the treatment of anaphylaxis (Section 4). 224 • a second-line treatment for cardiogenic shock. Dose during CPR. During cardiac arrest, the initial IV/IO dose of adrenaline is 1 mg. There are no studies showing improvement in survival or neurological outcomes with higher doses of adrenaline for patients in refractory cardiac arrest. 4 Following ROSC, even small doses of adrenaline (50-100 g) may induce tachycardia, myocardial ischaemia, VT and VF. Once a perfusing rhythm is established, if further adrenaline is deemed necessary, titrate the dose carefully to achieve an appropriate blood pressure. Intravenous doses of 50 g are usually sufficient for most hypotensive patients.
Use. Adrenaline is available most commonly in two dilutions:
• 1 in 10,000 (10 ml of this solution contains 1 mg of adrenaline) • 1 in 1000 (1 ml of this solution contains 1 mg of adrenaline).
Both these dilutions are used routinely in Europe.
Anti-arrhythmics
As with vasopressors, the evidence that anti-arrhythmic drugs are of benefit in cardiac arrest is limited. No anti-arrhythmic drug given during human cardiac arrest has been shown to increase survival to hospital discharge, although amiodarone has been shown to increase survival to hospital admission. 670, 671 Despite the lack of human long-term outcome data, the balance of evidence is in favour of the use anti-arrhythmic drugs for the management of arrhythmias in cardiac arrest. There is an ongoing trial comparing amiodarone to lidocaine and to placebo designed and powered to evaluate for functional survival. 312 
Amiodarone
Amiodarone is a membrane-stabilising anti-arrhythmic drug that increases the duration of the action potential and refractory period in atrial and ventricular myocardium. Atrioventricular conduction is slowed, and a similar effect is seen with accessory pathways. Amiodarone has a mild negative inotropic action and causes peripheral vasodilation through non-competitive alphablocking effects. The hypotension that occurs with intravenous amiodarone is related to the rate of delivery and is due more to the solvent (Polysorbate 80 and benzyl alcohol), which causes histamine release, rather than the drug itself. 672 A premixed formulation of intravenous amiodarone (PM101) that does not contain Polysorbate 80 and uses a cyclodextrin to maintain amiodarone in the aqueous phase is available in the United States. 673 Following three initial shocks, amiodarone in shock-refractory VF improves the short-term outcome of survival to hospital admission compared with placebo 670 or lidocaine. 671 Amiodarone also appears to improve the response to defibrillation when given to humans or animals with VF or haemodynamically unstable ventricular tachycardia. [674] [675] [676] [677] [678] There is no evidence to indicate the optimal time at which amiodarone should be given when using a single-shock strategy. In the clinical studies to date, the amiodarone was given if VF/pVT persisted after at least three shocks. For this reason, and in the absence of any other data, amiodarone 300 mg is recommended if VF/pVT persists after three shocks.
Indications. Amiodarone is indicated in:
• refractory VF/pVT • haemodynamically stable ventricular tachycardia (VT) and other resistant tachyarrhythmias (Section 11).
Dose during CPR. We recommend that an initial intravenous dose of 300 mg amiodarone, diluted in 5% glucose (or other suitable solvent) to a volume of 20 ml (or from a pre-filled syringe) should be given after three defibrillation attempts irrespective of whether they are consecutive shocks, or interrupted by CPR, or for recurrent VF/pVT during cardiac arrest. A further dose of 150 mg may be given after five defibrillation attempts. Amiodarone can cause thrombophlebitis when injected into a peripheral vein; use a central vein if a central venous catheter is in situ but, if not, use a large peripheral vein or the IO route followed by a generous flush.
Clinical aspects of use. Amiodarone may paradoxically be arrhythmogenic, especially if given concurrently with drugs that prolong the QT interval. However, it has a lower incidence of pro-arrhythmic effects than other anti-arrhythmic drugs under similar circumstances. The major acute adverse effects from amiodarone are hypotension and bradycardia in patients with ROSC, and can be treated with fluids and/or inotropic drugs. The side effects associated with prolonged oral use (abnormalities of thyroid function, corneal microdeposits, peripheral neuropathy, and pulmonary/hepatic infiltrates) are not relevant in the acute setting.
Lidocaine
Lidocaine is recommended for use during ALS when amiodarone is unavailable. 671 Lidocaine is a membrane-stabilising anti-arrhythmic drug that acts by increasing the myocyte refractory period. It decreases ventricular automaticity, and its local anaesthetic action suppresses ventricular ectopic activity. Lidocaine suppresses activity of depolarised, arrhythmogenic tissues while interfering minimally with the electrical activity of normal tissues. Therefore, it is effective in suppressing arrhythmias associated with depolarisation (e.g. ischaemia, digitalis toxicity) but is relatively ineffective against arrhythmias occurring in normally polarised cells (e.g. atrial fibrillation/flutter). Lidocaine raises the threshold for VF.
Lidocaine toxicity causes paraesthesia, drowsiness, confusion and muscular twitching progressing to convulsions. It is considered generally that a safe dose of lidocaine must not exceed 3 mg kg −1 over the first hour. If there are signs of toxicity, stop the infusion immediately; treat seizures if they occur. Lidocaine depresses myocardial function, but to a much lesser extent than amiodarone. The myocardial depression is usually transient and can be treated with intravenous fluids or vasopressors.
Indications. Lidocaine is indicated in refractory VF/pVT (when amiodarone is unavailable).
Dose. When amiodarone is unavailable, consider an initial dose of 100 mg (1-1.5 mg kg −1 ) of lidocaine for VF/pVT refractory to three shocks. Give an additional bolus of 50 mg if necessary. The total dose should not exceed 3 mg kg −1 during the first hour.
Clinical aspects of use. Lidocaine is metabolised by the liver, and its half-life is prolonged if the hepatic blood flow is reduced, e.g. in the presence of reduced cardiac output, liver disease or in the elderly. During cardiac arrest normal clearance mechanisms do not function, thus high plasma concentrations may be achieved after a single dose. After 24 h of continuous infusion, the plasma half-life increases significantly. Reduce the dose in these circumstances, and regularly review the indication for continued therapy. Lidocaine is less effective in the presence of hypokalaemia and hypomagnesaemia, which should be corrected immediately.
Magnesium
We recommend magnesium is not routinely used for the treatment of cardiac arrest. Studies in adults in and out of hospital have failed to demonstrate any increase in the rate of ROSC when magnesium is given routinely during CPR. [679] [680] [681] [682] [683] [684] Magnesium is an important constituent of many enzyme systems, especially those involved with ATP generation in muscle. It plays a major role in neurochemical transmission, where it decreases acetylcholine release and reduces the sensitivity of the motor endplate. Magnesium also improves the contractile response of the stunned myocardium, and limits infarct size by a mechanism that has yet to be fully elucidated. 685 The normal plasma range of magnesium is 0.8-1.0 mmol l −1 .
Hypomagnesaemia is often associated with hypokalaemia, and may contribute to arrhythmias and cardiac arrest. Hypomagnesaemia increases myocardial digoxin uptake and decreases cellular Na+/K + -ATP-ase activity. In patients with hypomagnesaemia, hypokalaemia, or both digitalis may become cardiotoxic even with therapeutic digitalis levels. Magnesium deficiency is not uncommon in hospitalised patients and frequently coexists with other electrolyte disturbances, particularly hypokalaemia, hypophosphataemia, hyponatraemia and hypocalcaemia.
Give an initial intravenous dose of 2 g (4 ml (8 mmol)) of 50% magnesium sulphate); it may be repeated after 10-15 min. Preparations of magnesium sulphate solutions differ among European countries.
Clinical aspects of use. Hypokalaemic patients are often hypomagnesaemic. If ventricular tachyarrhythmias arise, intravenous magnesium is a safe, effective treatment. Magnesium is excreted by the kidneys, but side effects associated with hypermagnesaemia are rare, even in renal failure. Magnesium inhibits smooth muscle contraction, causing vasodilation and a dose-related hypotension, which is usually transient and responds to intravenous fluids and vasopressors.
Calcium
Calcium plays a vital role in the cellular mechanisms underlying myocardial contraction. There is no data supporting any beneficial action for calcium after most cases of cardiac arrest [686] [687] [688] [689] [690] [691] ; conversely, other studies have suggested a possible adverse effect when given routinely during cardiac arrest (all rhythms). 692, 693 High plasma concentrations achieved after injection may be harmful to the ischaemic myocardium and may impair cerebral recovery. Give calcium during resuscitation only when indicated specifically, i.e. in pulseless electrical activity caused by:
• hyperkalaemia • hypocalcaemia • overdose of calcium channel-blocking drugs.
The initial dose of 10 ml 10% calcium chloride (6.8 mmol Ca 2+ ) may be repeated if necessary. Calcium can slow the heart rate and precipitate arrhythmias. In cardiac arrest, calcium may be given by rapid intravenous injection. In the presence of a spontaneous circulation give it slowly. Do not give calcium solutions and sodium bicarbonate simultaneously by the same route to avoid precipitation.
Buffers
Cardiac arrest results in combined respiratory and metabolic acidosis because pulmonary gas exchange ceases and cellular metabolism becomes anaerobic. The best treatment of acidaemia in cardiac arrest is CPR. During cardiac arrest, arterial gas values may be misleading and bear little relationship to the tissue acid-base state 394 ; analysis of central venous blood may provide a better estimation of tissue pH. Bicarbonate causes generation of carbon dioxide, which diffuses rapidly into cells. It has the following effects.
• It exacerbates intracellular acidosis.
• It produces a negative inotropic effect on ischaemic myocardium.
• It presents a large, osmotically active, sodium load to an already compromised circulation and brain.
• It produces a shift to the left in the oxygen dissociation curve, further inhibiting release of oxygen to the tissues.
Mild acidaemia causes vasodilation and can increase cerebral blood flow. Therefore, full correction of the arterial blood pH may theoretically reduce cerebral blood flow at a particularly critical time. As the bicarbonate ion is excreted as carbon dioxide via the lungs, ventilation needs to be increased.
Several animal and clinical studies have examined the use of buffers during cardiac arrest. Clinical studies using Tribonate ® 694 or sodium bicarbonate as buffers have failed to demonstrate any advantage. [694] [695] [696] [697] [698] [699] [700] [701] Two studies have found that EMS systems using sodium bicarbonate earlier and more frequently had significantly higher ROSC and hospital discharge rates and better long-term neurological outcome. 702, 703 . Animal studies have generally been inconclusive, but some have shown benefit in giving sodium bicarbonate to treat cardiovascular toxicity (hypotension, cardiac arrhythmias) caused by tricyclic antidepressants and other fast sodium channel blockers (Section 4). 224, 704, 705 Giving sodium bicarbonate routinely during cardiac arrest and CPR or after ROSC is not recommended. Consider sodium bicarbonate for:
• life-threatening hyperkalaemia • cardiac arrest associated with hyperkalaemia • tricyclic overdose.
Give 50 mmol (50 ml of an 8.4% solution) or 1 mmol kg −1 of sodium bicarbonate intravenously. Repeat the dose as necessary, but use acid/base analysis (either arterial, central venous or marrow aspirate from IO needle) to guide therapy. Severe tissue damage may be caused by subcutaneous extravasation of concentrated sodium bicarbonate. The solution is incompatible with calcium salts as it causes the precipitation of calcium carbonate.
Fibrinolysis during CPR
Fibrinolytic drugs may be used when pulmonary embolism is the suspected or known cause of cardiac arrest. Thrombus formation is a common cause of cardiac arrest, most commonly due to acute myocardial ischaemia following coronary artery occlusion by thrombus, but occasionally due to a dislodged venous thrombus causing a pulmonary embolism. The use of fibrinolytic drugs to break down coronary artery and pulmonary artery thrombus has been the subject of several studies. Fibrinolytics have also been demonstrated in animal studies to have beneficial effects on cerebral blood flow during cardiopulmonary resuscitation, 706, 707 and a clinical study has reported less anoxic encephalopathy after fibrinolytic therapy during CPR. 708 Several studies have examined the use of fibrinolytic therapy given during non-traumatic cardiac arrest unresponsive to standard therapy. [709] [710] [711] [712] [713] [714] [715] and some have shown non-significant improvements in survival to hospital discharge, 709, 712 and greater ICU survival. 708 A small series of case reports also reported survival to discharge in three cases refractory to standard therapy with VF or PEA treated with fibrinolytics. 716 Conversely, two large clinical trials 717, 718 failed to show any significant benefit for fibrinolytics in out-of-hospital cardiac arrest unresponsive to initial interventions.
Results from the use of fibrinolytics in patients suffering cardiac arrest from suspected pulmonary embolism have been variable. A meta-analysis, which included patients with pulmonary embolism as a cause of the arrest, concluded that fibrinolytics increased the rate of ROSC, survival to discharge and long-term neurological function. 719 Several other studies have demonstrated an improvement in ROSC and admission to hospital or the intensive care unit, but not in survival to neurologically intact hospital discharge. [709] [710] [711] [712] 714, 715, [720] [721] [722] [723] Although several relatively small clinical studies 709, 710, 712, 721 and case series 708, 716, [724] [725] [726] have not demonstrated any increase in bleeding complications with thrombolysis during CPR in non-traumatic cardiac arrest, a recent large study 718 and meta-analysis 719 have shown an increased risk of intracranial bleeding associated with the routine use of fibrinolytics during non-traumatic cardiac arrest. Successful fibrinolysis during cardiopulmonary resuscitation is usually associated with good neurological outcome. 719, 721, 722 Fibrinolytic therapy should not be used routinely in cardiac arrest. Consider fibrinolytic therapy when cardiac arrest is caused by proven or suspected acute pulmonary embolism. Following fibrinolysis during CPR for acute pulmonary embolism, survival and good neurological outcome have been reported in cases requiring in excess of 60 min of CPR. If a fibrinolytic drug is given in these circumstances, consider performing CPR for at least 60-90 min before termination of resuscitation attempts. [727] [728] [729] Ongoing CPR is not a contraindication to fibrinolysis. Treatment of pulmonary embolism is addressed in Section 4 including the role of extracorporeal CPR, and surgical or mechanical thrombectomy. 224 
Intravenous fluids
Hypovolaemia is a potentially reversible cause of cardiac arrest. Infuse fluids rapidly if hypovolaemia is suspected. In the initial stages of resuscitation there are no clear advantages to using colloid, so use balanced crystalloid solutions, Hartmann's solution or 0.9% sodium chloride. Avoid glucose, which is redistributed away from the intravascular space rapidly and causes hyperglycaemia, and may worsen neurological outcome after cardiac arrest. [730] [731] [732] [733] [734] [735] [736] [737] [738] Whether fluids should be infused routinely during cardiac arrest is controversial. There are no published human studies specifically aimed to evaluate the advantages of routine fluid use compared to no fluids during normovolaemic cardiac arrest. Three animal studies show that the increase in right atrial pressure produced by infusion of fluids during CPR decreases coronary perfusion pressure, [739] [740] [741] and another animal study 742 shows that the coronary perfusion pressure rise with adrenaline during CPR is not improved with the addition of a fluid infusion. In a clinical trial which randomised patients to rapid prehospital cooling, accomplished by infusing up to 2 L of 4 • C normal saline immediately after ROSC, the incidence of re-arrest and pulmonary oedema on first chest X-ray was significantly higher in the intervention group. 743 This was not confirmed by a similar study in which patients received a median of 1 L of cold saline before hospital admission. 744 Results of a further study on rapid prehospital cooling (NCT01173393) are awaited.
One animal study shows that hypertonic saline improves cerebral blood flow during CPR. 745 However, one small clinical study 746 and one randomised trial 747 have not shown any benefit with hypertonic fluid during CPR. One retrospective matched pair analysis of a German OHCA registry showed that use of hypertonic saline with 6% hydroxyethyl starch was associated with increased rates of survival to hospital admission. 748 However there are concerns regarding the use of colloids and starch solutions in particular in critically ill patients. 749 Ensure normovolaemia, but in the absence of hypovolaemia, infusion of an excessive volume of fluid is likely to be harmful. 750 Use intravenous fluid to flush peripherally injected drugs into the central circulation.
3h -CPR techniques and devices
At best, standard manual CPR produces coronary and cerebral perfusion that is just 30% of normal. 751 Several CPR techniques and devices aim to improve haemodynamics and survival when used by trained providers in selected cases. However, the success of any technique or device depends on the education and training of the rescuers and on resources (including personnel). In the hands of some groups, novel techniques and adjuncts may be better than standard CPR. However, a device or technique which provides good quality CPR when used by a highly trained team or in a test setting may show poor quality and frequent interruptions when used in an uncontrolled clinical setting. 752 It is prudent that rescuers are welltrained and that if a circulatory adjunct is used, a programme of continuous surveillance be in place to ensure that use of the adjunct does not adversely affect survival. Although manual chest compressions are often performed very poorly, [753] [754] [755] no adjunct has consistently been shown to be superior to conventional manual CPR.
Mechanical chest compression devices
Providing high-quality manual chest compressions can be challenging and there is evidence that CPR quality deteriorates with time. Automated mechanical chest compression devices may enable the delivery of high quality compressions especially in circumstances where this may not be possible with manual compressions -CPR in a moving ambulance where safety is at risk, prolonged CPR (e.g. hypothermic arrest), and CPR during certain procedures (e.g. coronary angiography or preparation for extracorporeal CPR). 347, 390, 414, [756] [757] [758] [759] [760] [761] Data from the US American CARES (Cardiac Arrest Registry to Enhance Survival) registry shows that 45% of participating EMS services use mechanical devices. 762 Since Guidelines 2010 there have been three large RCTs enrolling 7582 patients that have shown no clear advantage from the routine use of automated mechanical chest compression devices for OHCA. [763] [764] [765] Ensuring high-quality chest compressions with adequate depth, rate and minimal interruptions, regardless of whether they are delivered by machine or human is important. 766, 767 In addition mechanical compressions usually follow a period of manual compressions. 768 The transition from manual compressions to mechanical compressions whilst minimising interruptions to chest compression and avoiding delays in defibrillation is therefore an important aspect of using these devices.
We suggest that automated mechanical chest compression devices are not used routinely to replace manual chest compressions. We suggest that automated mechanical chest compression devices are a reasonable alternative to high-quality manual chest compressions in situations where sustained high-quality manual chest compressions are impractical or compromise provider safety. 4 Interruptions to CPR during device deployment should be avoided. Healthcare personnel who use mechanical CPR should do so only within a structured, monitored programme, which should include comprehensive competency-based training and regular opportunities to refresh skills.
The experience from the three large RCTs suggests that use of mechanical devices requires initial and on-going training and quality assurance to minimise interruptions in chest compression when transitioning from manual to mechanical compressions and preventing delays in defibrillation. The use of training drills and 'pit-crew' techniques for device deployment are suggested to help minimise interruptions in chest compression. [769] [770] [771] Our recommendation is generic for automated chest compression devices. Although there may be some device specific differences, they have not been directly compared in RCTs, and the three large RCTs [763] [764] [765] did not suggest a difference between the two most studied devices [the AutoPulse (Zoll Circulation, Chelmsford, Massachusetts, USA) and LUCAS-2 (Physio-Control Inc/Jolife AB, Lund, Sweden)] for critical and important patient outcomes when compared with the use of manual chest compressions alone. 4 Information concerning the routine use of mechanical devices for IHCA is limited. 772 One small RCT of 150 IHCA patients showed improved survival with mechanical chest compressions delivered by a piston device [Thumper 1007 CCV device (Michigan Instruments, Grand Rapids, Michigan, USA)] when compared with manual compressions (OR 2.81, 95% CI 1.26-6.24). 773 Lund University cardiac arrest system (LUCAS) CPR
The LUCAS delivers chest compression and active decompression through a piston system with suction cup. The current model is a battery driven device that delivers 100 compressions min −1 to a depth of 40-50 mm. There have been two large RCTs of the LUCAS device since the 2010 Guidelines. 764, 765 The LINC (LUCAS in cardiac arrest) RCT included 2589 adult OHCA patients and compared a modified CPR algorithm, which included mechanical chest compressions with a standard resuscitation algorithm which included manual chest compressions. 764 In the intention to treat analysis, there was no improvement in the primary outcome of 4-h survival (mechanical CPR 23.6% vs. manual CPR 23.7%, treatment difference −0.05%, 95% CI 3.3-3.2%; p > 0.99), 1 month survival (survival: 8.6% vs. 8.5%, treatment difference 0.16%, 95% CI 2.0-2.3%) and favourable neurological survival (8.1% vs. 7.3%, treatment difference 0.78%, 95% CI 1.3-2.8%). A follow-up study reported that patients who received LUCAS CPR were more likely to sustain injury (OR 3.4, 95% CI 1.55-7.31%), including rib fractures (OR 2.0, 95% CI 1.11-3.75%). 774 The PaRAMeDIC trial (Prehospital Randomised Assessment of a Mechanical Compression Device) trial was cluster RCT that randomised ambulance vehicles to LUCAS or control and included 4471 patients (1652 LUCAS, 2819 manual chest compressions). 765 The intention-to-treat analysis found no improvement in the primary outcome of 30-day survival (LUCAS CPR 6% vs. manual CPR 7%, adjusted OR 0.86, 95% CI 0.64-1.15). Survival with a favourable neurological outcome at three months was lower amongst patients randomised to LUCAS CPR (5% vs. 6%, adjusted OR 0.72, 95% CI 0.52-0.99). In addition, in patients with VF/pVT, there was a lower 30-day survival with LUCAS CPR (OR 0.71, 95% CI 0.52-0.98). Delays in attempted defibrillation caused by device deployment may have caused this.
A meta-analysis of the three LUCAS RCTs that included 7178 patients with OHCA was included in the PARAMEDIC publication. 764, 765, 775 and reported similar initial and long-term survival (survived event OR 1.00, 95% CI 0.90-1.11; survival to discharge/30-days OR 0.96, 95% CI 0.80-1.15). Meta-analysis from the two larger RCTs noted significant heterogeneity (I 2 = 69%) but no overall difference in neurological outcomes between LUCAS and manual chest compressions (random effects model OR 0.93, 95% CI 0.64-1.33). 764, 765 Load-distributing band CPR (AutoPulse)
The load-distributing band (LDB) is a battery-powered device consisting of a large backboard and a band that encircles the patient's chest. Compressions are delivered at a rate of 80 min −1 by tightening of the band. The evidence from clinical trials considered for the LDB in 2010 was conflicting. Evidence from one OHCA multi-centre RCT showed no improvement in 4-h survival and worse neurological outcome with LDB-CPR. 776 A further study showed lower odds of 30-day survival (OR 0.4) but subgroup analysis showed an increased rate of ROSC in LDB-CPR treated patients. 777 Non-randomised trials reported increased rates of sustained ROSC, 778, 779 increased survival to discharge following OHCA 779 and improved haemodynamics following failed resuscitation from in-hospital cardiac arrest. 780 A recent large RCT showed similar outcomes for LDB and manual CPR. 763 The CIRC (Circulation Improving Resuscitation Care) trial, an equivalence RCT, randomised 4753 adult OHCA patients to the LDB or manual chest compressions. After a predefined adjustment for covariates and multiple interim analyses the adjusted OR was 1.06 (95% CI 0.83-1.37) and within the pre-defined region of equivalence for the primary outcome of survival to discharge (manual CPR vs. LDB CPR 11.0% vs. 9.4%). Good neurological survival to hospital discharge was similar (mechanical CPR 44.4% vs. manual CPR 48.1%, adjusted OR 0.80, 95% CI 0.47-1.37).
Open-chest CPR
Open-chest CPR produces better coronary perfusion coronary pressure than standard CPR and may be indicated for patients with cardiac arrest caused by trauma, 781 in the early postoperative phase after cardiothoracic surgery 782, 783 (see Section 4 -special circumstances 224 ) or when the chest or abdomen is already open (transdiaphragmatic approach), for example, in trauma surgery. 784 
Active compression-decompression CPR (ACD-CPR)
ACD-CPR is achieved with a hand-held device equipped with a suction cup to lift the anterior chest actively during decompression. Decreasing intrathoracic pressure during the decompression phase increases venous return to the heart and increases cardiac output and subsequent coronary and cerebral perfusion pressures during the compression phase. [785] [786] [787] [788] Results of ACD-CPR have been mixed. In some clinical studies ACD-CPR improved haemodynamics compared with standard CPR, 786, [788] [789] [790] but in another study it did not. 791 In three randomised studies, 790, 792, 793 ACD-CPR improved long-term survival after out-of-hospital cardiac arrest; however, in five other randomised studies, ACD-CPR made no difference to outcome. [794] [795] [796] [797] [798] The efficacy of ACD-CPR may be highly dependent on the quality and duration of training. 799 A meta-analysis of 10 trials of out-of-hospital cardiac arrest and two of in-hospital cardiac arrest showed no early or late survival benefit to ACD-CPR over conventional CPR 234, 800 and this is confirmed by another recent meta-analysis. 801 Two post-mortem studies have shown more rib and sternal fractures after ACD-CPR compared with conventional CPR, 802, 803 but another found no difference. 804 
Impedance threshold device (ITD)
The impedance threshold device (ITD) is a valve that limits air entry into the lungs during chest recoil between chest compressions; this decreases intrathoracic pressure and increases venous return to the heart. When used with a cuffed tracheal tube and active compression-decompression (ACD), [805] [806] [807] the ITD is thought to act synergistically to enhance venous return during active decompression. The ITD has also been used during conventional CPR with a tracheal tube or facemask. 808 If rescuers can maintain a tight face-mask seal, the ITD may create the same negative intrathoracic pressure as when used with a tracheal tube. 808 An RCT of the ITD with standard CPR compared to standard CPR alone with 8718 OHCA patients failed to show any benefit with ITD use in terms of survival and neurological outcome. 809 We therefore recommend that the ITD is not used routinely with standard CPR.
Two RCTs did not show a benefit in terms of survival to hospital discharge of the ITD with active compression decompression CPR when compared with active compression decompression CPR alone. 805, 810 Results of a large trial of a combination of ITD with active compression decompression CPR (ACD CPR) compared to standard CPR was reported in two publications. The primary publication reported the results from 2470 patients with OHCA 811 whereas the secondary publication reported results from those with non-traumatic cardiac arrest (n = 27380). 812 This study did detect a statistically significant difference in neurologically favourable survival at discharge, and survival at 12 months but no difference for survival to discharge and neurologically favourable survival at 12 months. 4 After consideration of the number needed to treat a decision was made not to recommend the routine use of the ITD and ACD. 4
3i -Peri-arrest arrhythmias
The correct identification and treatment of arrhythmias in the critically ill patient may prevent cardiac arrest from occurring or reoccurring after successful initial resuscitation. The treatment algorithms described in this section have been designed to enable the non-specialist ALS provider to treat the patient effectively and safely in an emergency; for this reason, they have been kept as simple as possible. If patients are not acutely ill there may be several other treatment options, including the use of drugs (oral or parenteral) that will be less familiar to the non-expert. In this situation there will be time to seek advice from cardiologists or other senior doctors with the appropriate expertise.
More comprehensive information on the management of arrhythmias can be found at www.escardio.org.
Principles of treatment
The initial assessment and treatment of a patient with an arrhythmia should follow the ABCDE approach. Key elements in this process include assessing for adverse signs; oxygen if indicated and guided by pulse oximetry; obtaining intravenous access, and establishing monitoring (ECG, blood pressure, SpO 2 ). Whenever possible, record a 12-lead ECG; this will help determine the precise rhythm, either before treatment or retrospectively. Correct any electrolyte abnormalities (e.g. K + , Mg 2+ , Ca 2+ ). Consider the cause and context of arrhythmias when planning treatment.
The assessment and treatment of all arrhythmias addresses two factors: the condition of the patient (stable versus unstable), and the nature of the arrhythmia. Anti-arrhythmic drugs are slower in onset and less reliable than electrical cardioversion in converting a tachycardia to sinus rhythm; thus, drugs tend to be reserved for stable patients without adverse signs, and electrical cardioversion is usually the preferred treatment for the unstable patient displaying adverse signs.
Adverse signs
The presence or absence of adverse signs or symptoms will dictate the appropriate treatment for most arrhythmias. The following adverse factors indicate a patient who is unstable because of the arrhythmia.
1. Shock -this is seen as pallor, sweating, cold and clammy extremities (increased sympathetic activity), impaired consciousness (reduced cerebral blood flow), and hypotension (e.g. systolic blood pressure < 90 mmHg). 2. Syncope -loss of consciousness, which occurs as a consequence of reduced cerebral blood flow 3. Heart failure -arrhythmias compromise myocardial performance by reducing coronary artery blood flow. In acute situations this is manifested by pulmonary oedema (failure of the left ventricle) and/or raised jugular venous pressure, and hepatic engorgement (failure of the right ventricle). 4. Myocardial ischaemia -this occurs when myocardial oxygen consumption exceeds delivery. Myocardial ischaemia may present with chest pain (angina) or may occur without pain as an isolated finding on the 12-lead ECG (silent ischaemia). The presence of myocardial ischaemia is especially important if there is underlying coronary artery disease or structural heart disease because it may cause further life-threatening complications including cardiac arrest.
Treatment options
Having determined the rhythm and the presence or absence of adverse signs, the options for immediate treatment are categorised as:
1. Electrical (cardioversion, pacing).
Pharmacological (anti-arrhythmic (and other) drugs).
Tachycardias If the patient is unstable
If the patient is unstable and deteriorating, with any of the adverse signs and symptoms described above being caused by the tachycardia, attempt synchronised cardioversion immediately (Fig. 3.4) . In patients with otherwise normal hearts, serious signs and symptoms are uncommon if the ventricular rate is <150 beats min −1 . Patients with impaired cardiac function or significant comorbidity may be symptomatic and unstable at lower heart rates. If cardioversion fails to restore sinus rhythm and the patient remains unstable, give amiodarone 300 mg intravenously over 10-20 min and re-attempt electrical cardioversion. The loading dose of amiodarone can be followed by an infusion of 900 mg over 24 h.
Repeated attempts at electrical cardioversion are not appropriate for recurrent (within hours or days) paroxysms (selfterminating episodes) of atrial fibrillation. This is relatively common in critically ill patients who may have ongoing precipitating factors causing the arrhythmia (e.g. metabolic disturbance, sepsis). Cardioversion does not prevent subsequent arrhythmias. If there are recurrent episodes, treat them with drugs.
Synchronised electrical cardioversion. If electrical cardioversion is used to convert atrial or ventricular tachyarrhythmias, the shock must be synchronised with the R wave of the ECG rather than with the T wave. 813 By avoiding the relative refractory period in this way, the risk of inducing ventricular fibrillation is minimised. Conscious patients must be anaesthetised or sedated before synchronised cardioversion is attempted. For a broad-complex tachycardia and AF, start with 120-150 J biphasic and increase in increments if this fails. Atrial flutter and paroxysmal supraventricular tachycardia (SVT) will often convert with lower energies: start with 70-120-J biphasic.
If the patient is stable
If the patient with tachycardia is stable (no adverse signs or symptoms) and is not deteriorating, pharmacological treatment may be possible. Evaluate the rhythm using a 12-lead ECG and assess the QRS duration. If the QRS duration is greater than 0.12 s (3 small squares on standard ECG paper) it is classified as a broad complex tachycardia. If the QRS duration is less than 0.12 s it is a narrow complex tachycardia.
All anti-arrhythmic treatments -physical manoeuvres, drugs, or electrical treatment -can also be pro-arrhythmic, so that clinical deterioration may be caused by the treatment rather than lack of effect. The use of multiple anti-arrhythmic drugs or high doses of a single drug can cause myocardial depression and hypotension. This may cause a deterioration of the cardiac rhythm. Expert help should be sought before using repeated doses or combinations of anti-arrhythmic drugs.
Broad-complex tachycardia
Broad-complex tachycardias are usually ventricular in origin. Although broad-complex tachycardias may be caused by supraventricular rhythms with aberrant conduction, in the unstable patient in the peri-arrest context assume they are ventricular in origin. In the stable patient with broad-complex tachycardia, the next step is to determine if the rhythm is regular or irregular.
Regular broad complex tachycardia. A regular broad-complex tachycardia is likely to be ventricular tachycardia or SVT with bundle branch block. If there is uncertainty about the source of the arrhythmia, give intravenous adenosine (using the strategy described below) as it may convert the rhythm to sinus and help diagnose the underlying rhythm.
Stable ventricular tachycardia can be treated with amiodarone 300 mg intravenously over 20-60 min followed by an infusion of 900 mg over 24 h. Specialist advice should be sought before considering alternatives treatments such as procainamide, nifekalant or sotalol.
Irregular broad complex tachycardia. Irregular broad complex tachycardia is most likely to be AF with bundle branch block. Another possible cause is AF with ventricular pre-excitation (Wolff-Parkinson-White (WPW) syndrome). In this case there is more variation in the appearance and width of the QRS complexes than in AF with bundle branch block. A third possible cause is polymorphic VT (e.g. torsade de pointes), although this rhythm is relatively unlikely to be present without adverse features.
Seek expert help with the assessment and treatment of irregular broad-complex tachyarrhythmia. If treating AF with bundle branch block, treat as for AF (see below). If pre-excited AF (or atrial flutter) is suspected, avoid adenosine, digoxin, verapamil and diltiazem. These drugs block the AV node and cause a relative increase in pre-excitation -this can provoke severe tachycardias. Electrical cardioversion is usually the safest treatment option.
Treat torsades de pointes VT immediately by stopping all drugs known to prolong the QT interval. Correct electrolyte abnormalities, especially hypokalaemia. Give magnesium sulphate 2 g, intravenously over 10 min. Obtain expert help, as other treatment (e.g. overdrive pacing) may be indicated to prevent relapse once the arrhythmia has been corrected. If adverse features develop (which is usual), arrange immediate synchronised cardioversion. If the patient becomes pulseless, attempt defibrillation immediately (cardiac arrest algorithm).
Narrow-complex tachycardia
The first step in the assessment of a narrow complex tachycardia is to determine if it is regular or irregular.
The commonest regular narrow-complex tachycardias include:
• sinus tachycardia;
• AV nodal re-entry tachycardia (AVNRT, the commonest type of SVT); • AV re-entry tachycardia (AVRT), which is associated with Wolff-Parkinson-White (WPW) syndrome; • atrial flutter with regular AV conduction (usually 2:1).
Irregular narrow-complex tachycardia is most commonly AF or sometimes atrial flutter with variable AV conduction ('variable block').
Regular narrow-complex tachycardia.
Sinus tachycardia. Sinus tachycardia is a common physiological response to a stimulus such as exercise or anxiety. In a sick patient it may be seen in response to many stimuli, such as pain, fever, anaemia, blood loss and heart failure. Treatment is almost always directed at the underlying cause; trying to slow sinus tachycardia will make the situation worse.
AVNRT and AVRT (paroxysmal SVT). AVNRT is the commonest type of paroxysmal SVT, often seen in people without any other form of heart disease and is relatively uncommon in a periarrest setting. 814 It causes a regular narrow-complex tachycardia, often with no clearly visible atrial activity on the ECG. Heart rates are usually well above the typical range of sinus rates at rest (60-120 beats min −1 ). It is usually benign, unless there is additional co-incidental structural heart disease or coronary disease.
AV re-entry tachycardia (AVRT) is seen in patients with the WPW syndrome and is also usually benign unless there happens to be additional structural heart disease. The common type of AVRT is a regular narrow-complex tachycardia, also often having no visible atrial activity on the ECG.
Atrial flutter with regular AV conduction (often 2:1 block). Atrial flutter with regular AV conduction (often 2:1 block) produces a regular narrow-complex tachycardia in which it may be difficult to see atrial activity and identify flutter waves with confidence, so it may be indistinguishable initially from AVNRT and AVRT. When atrial flutter with 2:1 block or even 1:1 conduction is accompanied by bundle branch block, it produces a regular broad-complex tachycardia that will usually be very difficult to distinguish from VT. Treatment of this rhythm as if it were VT will usually be effective, or will lead to slowing of the ventricular response and identification of the rhythm. Most typical atrial flutter has an atrial rate of about 300 beats min −1 , so atrial flutter with 2:1 block tends to produce a tachycardia of about 150 beats min −1 . Much faster rates are unlikely to be due to atrial flutter with 2:1 block.
Treatment of regular narrow complex tachycardia. If the patient is unstable with adverse features caused by the arrhythmia, attempt synchronised electrical cardioversion. It is reasonable to give adenosine to an unstable patient with a regular narrowcomplex tachycardia while preparations are made for synchronised cardioversion; however, do not delay electrical cardioversion if the adenosine fails to restore sinus rhythm. In the absence of adverse features, proceed as follows.
• Start with vagal manoeuvres 814 : carotid sinus massage or the Valsalva manoeuvre will terminate up to a quarter of episodes of paroxysmal SVT. Carotid sinus massage stimulates baroreceptors, which increase vagal tone and reduces sympathetic drive, which slows conduction via the AV node. Carotid sinus massage is given by applying pressure over the carotid artery at the level of the cricoid cartilage. Massage the area with firm circular movements for about 5 s. If this does not terminate the arrhythmia, repeat on the opposite side. Avoid carotid massage if a carotid bruit is present: rupture of an atheromatous plaque could cause cerebral embolism and stroke. A Valsalva manoeuvre (forced expiration against a closed glottis) in the supine position may be the most effective technique. A practical way of achieving this without protracted explanation is to ask the patient to blow into a 20 ml syringe with enough force to push back the plunger. Record an ECG (preferably multi-lead) during each manoeuvre. If the rhythm is atrial flutter, slowing of the ventricular response will often occur and demonstrate flutter waves.
• If the arrhythmia persists and is not atrial flutter, use adenosine. Give 6 mg as a rapid intravenous bolus. Record an ECG (preferably multi-lead) during each injection. If the ventricular rate slows transiently but the arrhythmia then persists, look for atrial activity such as atrial flutter or other atrial tachycardia and treat accordingly. If there is no response to adenosine 6 mg, give a 12 mg bolus; if there is no response, give one further 12 mgbolus. This strategy will terminate 90-95% of supraventricular arrhythmias.
• Successful termination of a tachyarrhythmia by vagal manoeuvres or adenosine indicates that it was almost certainly AVNRT or AVRT. Monitor the patients for further rhythm abnormalities. Treat recurrence either with further adenosine or with a longer-acting drug with AV nodal-blocking action (e.g. diltiazem or verapamil).
• If adenosine is contraindicated or fails to terminate a regular narrow-complex tachycardia without demonstrating that it is atrial flutter, give a calcium channel blocker (e.g. verapamil or diltiazem).
Irregular narrow-complex tachycardia
An irregular narrow-complex tachycardia is most likely to be AF with an uncontrolled ventricular response or, less commonly, atrial flutter with variable AV block. Record a 12-lead ECG to identify the rhythm. If the patient is unstable with adverse features caused by the arrhythmia, attempt synchronised electrical cardioversion as described above. The European Society of Cardiology provides detailed guidelines on the management of AF: www.escardio.org.
If there are no adverse features, treatment options include:
• rate control by drug therapy • rhythm control using drugs to encourage chemical cardioversion • rhythm control by electrical cardioversion • treatment to prevent complications (e.g. anticoagulation).
Obtain expert help to determine the most appropriate treatment for the individual patient. The longer a patient remains in AF, the greater is the likelihood of atrial clot developing. In general, patients who have been in AF for more than 48 h should not be treated by cardioversion (electrical or chemical) until they have received full anticoagulation or absence of atrial clot has been shown by transoesophageal echocardiography. If the clinical scenario dictates that cardioversion is required and the duration of AF is greater than 48 h (or the duration is unknown) discuss anticoagulation, choice of agent, and duration with a cardiologist.
If the aim is to control heart rate, the drugs of choice are betablockers and diltiazem. Digoxin and amiodarone may be used in patients with heart failure.
If the duration of AF is less than 48 h and rhythm control is considered appropriate, chemical cardioversion may be attempted. Seek expert help and consider, flecainide, propafenone, or ibutilide. Amiodarone (300 mg intravenously over 20-60 min followed by 900 mg over 24 h) may also be used but is less effective. Electrical cardioversion remains an option in this setting and will restore sinus rhythm in more patients than chemical cardioversion.
Seek expert help if any patient with AF is known or found to have ventricular pre-excitation (WPW syndrome). Avoid using adenosine, diltiazem, verapamil or digoxin in patients with pre-excited AF or atrial flutter, as these drugs block the AV node and cause a relative increase in pre-excitation.
Bradycardia
A bradycardia is defined as a heart rate of <60 beats min −1 . Bradycardia can have cardiac causes (e.g. myocardial infarction; myocardial ischaemia; sick sinus syndrome), non-cardiac causes (e.g. vasovagal response, hypothermia; hypoglycaemia; hypothyroidism, raised intracranial pressure) or be caused by drug toxicity (e.g. digoxin; beta blockers; calcium channel blockers).
Bradycardias are caused by reduced sinoatrial node firing or failure of the atrial-ventricular conduction system. Reduced sinoatrial node firing is seen in sinus bradycardia (caused by excess vagal tone), sinus arrest, and sick sinus syndrome. Atrioventricular (AV) blocks are divided into first, second, and third degrees and may be associated with multiple medications or electrolyte disturbances, as well as structural problems caused by acute myocardial infarction and myocarditis. A first-degree AV block is defined by a prolonged P-R interval (>0.20 s), and is usually benign. Seconddegree AV block is divided into Mobitz types I and II. In Mobitz type I, the block is at the AV node, is often transient and may be asymptomatic. In Mobitz type II, the block is most often below the AV node at the bundle of His or at the bundle branches, and is often symptomatic, with the potential to progress to complete AV block. Third-degree heart block is defined by AV dissociation, which may be permanent or transient, depending on the underlying cause.
Initial assessment
Assess the patient with bradycardia using the ABCDE approach. Consider the potential cause of the bradycardia and look for the adverse signs. Treat any reversible causes of bradycardia identified in the initial assessment. If adverse signs are present start to treat the bradycardia. Initial treatments are pharmacological, with pacing being reserved for patients unresponsive to pharmacological treatments or with risks factors for asystole (Fig. 3.5 ).
Pharmacological treatment
If adverse signs are present, give atropine 500 g, intravenously and, if necessary, repeat every 3-5 min to a total of 3 mg. Doses of atropine of less than 500 g, paradoxically, may cause further slowing of the heart rate. 815 In healthy volunteers a dose of 3 mg produces the maximum achievable increase in resting heart rate. 816 Use atropine cautiously in the presence of acute coronary ischaemia or myocardial infarction; increased heart rate may worsen ischaemia or increase the zone of infarction.
If treatment with atropine is ineffective, consider second line drugs. These include isoprenaline (5 g min −1 starting dose), adrenaline (2-10 g min −1 ) and dopamine (2-10 g kg −1 min −1 ). Theophylline (100-200 mg slow intravenous injection) should be considered if the bradycardia is caused by inferior myocardial infarction, cardiac transplant or spinal cord injury. Consider giving intravenous glucagon if beta-blockers or calcium channel blockers are a potential cause of the bradycardia. Do not give atropine to patients with cardiac transplants -it can cause a high-degree AV block or even sinus arrest. 817 
Pacing
Initiate transcutaneous pacing immediately if there is no response to atropine, or if atropine is unlikely to be effective.
Transcutaneous pacing can be painful and may fail to produce effective mechanical capture. Verify mechanical capture and reassess the patient's condition. Use analgesia and sedation to control pain, and attempt to identify the cause of the bradyarrhythmia.
If atropine is ineffective and transcutaneous pacing is not immediately available, fist pacing can be attempted while waiting for pacing equipment. Give serial rhythmic blows with the closed fist over the left lower edge of the sternum to pace the heart at a physiological rate of 50-70 beats min −1 .
Seek expert help to assess the need for temporary transvenous pacing. Temporary transvenous pacing should be considered if there are is a history of recent asystole; Mobitz type II AV block; complete (third-degree) heart block (especially with broad QRS or initial heart rate < 40 beats min −1 ) or evidence of ventricular standstill of more than 3 s.
Antiarrhythmic drugs Adenosine
Adenosine is a naturally occurring purine nucleotide. It slows transmission across the AV node but has little effect on other myocardial cells or conduction pathways. It is highly effective for terminating paroxysmal SVT with re-entrant circuits that include the AV node (AVNRT). In other narrow-complex tachycardias, adenosine will reveal the underlying atrial rhythms by slowing the ventricular response. It has an extremely short half-life of 10-15 s and, therefore, is given as a rapid bolus into a fast running intravenous infusion or followed by a saline flush. The smallest dose likely to be effective is 6 mg (which is outside some current licences for an initial dose) and, if unsuccessful this can be followed with up to two doses each of 12 mg every 1-2 min. Patients should be warned of transient unpleasant side effects, in particular nausea, flushing, and chest discomfort. Adenosine is not available in some European countries, but adenosine triphosphate (ATP) is an alternative. In a few European countries neither preparation may be available; verapamil is probably the next best choice. Theophylline and related compounds block the effect of adenosine. Patients receiving dipyridamole or carbamazepine, or with denervated (transplanted) hearts, display a markedly exaggerated effect that may be hazardous. In these patients, or if injected into a central vein, reduce the initial dose of adenosine to 3 mg. In the presence of WPW syndrome, blockage of conduction across the AV node by adenosine may promote conduction across an accessory pathway. In the presence of supraventricular arrhythmias this may cause a dangerously rapid ventricular response. In the presence of WPW syndrome, rarely, adenosine may precipitate atrial fibrillation associated with a dangerously rapid ventricular response.
Amiodarone
Intravenous amiodarone has effects on sodium, potassium and calcium channels as well as alpha-and beta-adrenergic blocking properties. Indications for intravenous amiodarone include:
• Control of haemodynamically stable monomorphic VT, polymorphic VT and wide-complex tachycardia of uncertain origin.
• Paroxysmal SVT uncontrolled by adenosine, vagal manoeuvres or AV nodal blockade; • to control rapid ventricular rate due to accessory pathway conduction in pre-excited atrial arrhythmias. In patients with pre-excitation and AF, digoxin, non-dihydropyridine calcium channel antagonists, or intravenous amiodarone should not be administered as they may increase the ventricular response and may result in VF. 818, 819 • Unsuccessful electrical cardioversion.
Give amiodarone, 300 mg intravenously, over 10-60 min depending on the circumstances and haemodynamic stability of the patient. This loading dose is followed by an infusion of 900 mg over 24 h. Additional infusions of 150 mg can be repeated as necessary for recurrent or resistant arrhythmias to a maximum manufacturer-recommended total daily dose of 2 g (this maximum licensed dose varies between different countries). In patients with severely impaired heart function, intravenous amiodarone is preferable to other anti-arrhythmic drugs for atrial and ventricular arrhythmias. Major adverse effects from amiodarone are hypotension and bradycardia, which can be prevented by slowing the rate of drug infusion. The hypotension associated with amiodarone is caused by vasoactive solvents (Polysorbate 80 and benzyl alcohol). An aqueous formulation of amiodarone does not contain these solvents and causes no more hypotension than lidocaine. 677 Whenever possible, intravenous amiodarone should be given via a central venous catheter; it causes thrombophlebitis when infused into a peripheral vein. In an emergency it can be injected into a large peripheral vein.
Calcium channel blockers: verapamil and diltiazem
Verapamil and diltiazem are calcium channel blocking drugs that slow conduction and increase refractoriness in the AV node. Intravenous diltiazem is not available in some countries. These actions may terminate re-entrant arrhythmias and control ventricular response rate in patients with a variety of atrial tachycardias. Indications include:
• stable regular narrow-complex tachycardias uncontrolled or unconverted by adenosine or vagal manoeuvres; • to control ventricular rate in patients with AF or atrial flutter and preserved ventricular function.
The initial dose of verapamil is 2.5-5 mg intravenously given over 2 min. In the absence of a therapeutic response or druginduced adverse event, give repeated doses of 5-10 mg every 15-30 min to a maximum of 20 mg. Verapamil should be given only to patients with narrow-complex paroxysmal SVT or arrhythmias known with certainty to be of supraventricular origin. The administration of calcium channel blockers to a patient with ventricular tachycardia may cause cardiovascular collapse.
Diltiazem at a dose of 250 g kg −1 intravenously, followed by a second dose of 350 g kg −1 , is as effective as verapamil. Verapamil and, to a lesser extent, diltiazem may decrease myocardial contractility and critically reduce cardiac output in patients with severe LV dysfunction. For the reasons stated under adenosine (above), calcium channel blockers are considered harmful when given to patients with AF or atrial flutter associated with pre-excitation (WPW) syndrome.
Beta-adrenergic blockers
Beta-blocking drugs (atenolol, metoprolol, labetalol (alpha-and beta-blocking effects), propranolol, esmolol) reduce the effects of circulating catecholamines and decrease heart rate and blood pressure. They also have cardioprotective effects for patients with acute coronary syndromes. Beta-blockers are indicated for the following tachycardias:
• narrow-complex regular tachycardias uncontrolled by vagal manoeuvres and adenosine in the patient with preserved ventricular function; • to control rate in AF and atrial flutter when ventricular function is preserved.
The intravenous dose of atenolol (beta 1 ) is 5 mg given over 5 min, repeated if necessary after 10 min. Metoprolol (beta 1 ) is given in doses of 2-5 mg at 5-min intervals to a total of 15 mg. Propranolol (beta 1 and beta 2 effects), 100 g kg −1 , is given slowly in three equal doses at 2-3-min intervals.
Intravenous esmolol is a short-acting (half-life of 2-9 min) beta 1 -selective beta-blocker. It is given as an intravenous loading dose of 500 g kg −1 over 1 min, followed by an infusion of 50-200 g kg −1 min −1 .
Side effects of beta-blockade include bradycardia, AV conduction delay and hypotension. Contraindications to the use of beta-adrenergic blocking drugs include second-or third-degree heart block, hypotension, severe congestive heart failure and lung disease associated with bronchospasm.
Magnesium
Magnesium is the first line treatment for polymorphic ventricular tachycardia (torsades de pointes) and ventricular or supraventricular tachycardia associated with hypomagnesaemia. It may also reduce ventricular rate in atrial fibrillation. Give magnesium sulphate 2 g (8 mmol) over 10 min. This can be repeated once if necessary.
